Merit Medical Systems (MMSI) 10-K 12 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 10, 2014	Jun. 30, 2013
Document Information [Abstract]	'	'	'
Entity Registrant Name	'MERIT MEDICAL SYSTEMS INC	'	'
Entity Central Index Key	'0000856982	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	42,862,172	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$452,137,252

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash and cash equivalents	$7,459,000	$9,719,000
Trade receivables — net of allowance for uncollectible accounts — 2013 — $840 and 2012 — $892	60,186,000	53,402,000
Employee receivables	224,000	169,000
Other receivables	3,279,000	2,672,000
Inventories	82,378,000	84,599,000
Prepaid expenses	5,121,000	4,133,000
Prepaid income taxes	1,232,000	1,250,000
Deferred income tax assets	5,638,000	4,976,000
Income tax refund receivables	398,000	1,076,000
Total current assets	165,915,000	161,996,000
PROPERTY AND EQUIPMENT:	'	'
Land and land improvements	16,240,000	17,346,000
Buildings	127,747,000	81,223,000
Manufacturing equipment	136,768,000	117,601,000
Furniture and fixtures	32,327,000	26,307,000
Leasehold improvements	13,692,000	13,236,000
Construction-in-progress	25,172,000	74,643,000
Total property and equipment	351,946,000	330,356,000
Less accumulated depreciation	-108,676,000	-95,553,000
Property and equipment — net	243,270,000	234,803,000
OTHER ASSETS:	'	'
Goodwill	184,505,000	175,108,000
Deferred income tax assets	800,000	4,237,000
Other assets	13,806,000	11,034,000
Total other assets	319,098,000	308,510,000
TOTAL	728,283,000	705,309,000
CURRENT LIABILITIES:	'	'
Trade payables	26,511,000	34,637,000
Accrued expenses	27,702,000	27,269,000
Current portion of long-term debt	10,000,000	10,000,000
Advances from employees	292,000	551,000
Income taxes payable	1,089,000	547,000
Total current liabilities	65,594,000	73,004,000
LONG-TERM DEBT	238,854,000	227,566,000
DEFERRED INCOME TAX LIABILITIES	2,548,000	2,373,000
LIABILITIES RELATED TO UNRECOGNIZED TAX BENEFITS	2,031,000	2,938,000
DEFERRED COMPENSATION PAYABLE	7,833,000	5,956,000
DEFERRED CREDITS	3,065,000	2,980,000
OTHER LONG-TERM OBLIGATIONS	2,652,000	8,915,000
Total liabilities	322,577,000	323,732,000
COMMITMENTS AND CONTINGENCIES (Notes 2, 7, 8, 9 and 13)	'	'
STOCKHOLDERS’ EQUITY:	'	'
Preferred stock — 5,000 shares authorized as of December 31, 2013 and 2012; no shares issued	'	'
Common stock, no par value; shares authorized — 2013 and 2012 - 100,000; issued and outstanding as of December 31, 2013 - 42,846 and December 31, 2012 - 42,489	177,775,000	172,341,000
Retained earnings	226,988,000	210,418,000
Accumulated other comprehensive income (loss)	943,000	-1,182,000
Total stockholders’ equity	405,706,000	381,577,000
TOTAL	728,283,000	705,309,000
Developed technology — net of accumulated amortization — 2013 — $17,602 and 2012 — $8,146	'	'
OTHER ASSETS:	'	'
Intangible Assets	91,052,000	87,332,000
Other — net of accumulated amortization — 2013 — $18,870 and 2012 — $14,034	'	'
OTHER ASSETS:	'	'
Intangible Assets	$28,935,000	$30,799,000

CONSOLIDATED_BALANCE_SHEETS_CO

CONSOLIDATED BALANCE SHEETS CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Share data, unless otherwise specified
CURRENT ASSETS:	'	'
Trade receivables, allowances (in dollars)	$840	$892
STOCKHOLDERS’ EQUITY:	'	'
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Common Stock, Par or Stated Value Per Share	'	'
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	42,846,000	42,489,000
Other	'	'
OTHER ASSETS:	'	'
Intangibles, accumulated amortization (in dollars)	18,870	14,034
Developed technology	'	'
OTHER ASSETS:	'	'
Intangibles, accumulated amortization (in dollars)	$17,602	$8,146

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Statement [Abstract]	'	'	'
NET SALES	$449,049	$394,288	$359,449
COST OF SALES	254,682	212,296	193,981
GROSS PROFIT	194,367	181,992	165,468
OPERATING EXPENSES:	'	'	'
Selling, general, and administrative	128,642	122,106	104,502
Research and development	33,886	27,795	21,938
Intangible asset impairment charges	8,089	0	0
Contingent consideration benefit	-4,094	0	0
Acquired in-process research and development	0	2,450	5,838
Total operating expenses	166,523	152,351	132,278
INCOME FROM OPERATIONS	27,844	29,641	33,190
OTHER INCOME (EXPENSE):	'	'	'
Interest income	255	226	129
Interest expense	-8,044	-604	-789
Other income (expense) — net	-216	-1,645	345
Other expense — net	-8,005	-2,023	-315
INCOME BEFORE INCOME TAXES	19,839	27,618	32,875
INCOME TAX EXPENSE	3,269	7,908	9,831
NET INCOME	$16,570	$19,710	$23,044
EARNINGS PER COMMON SHARE:	'	'	'
Basic (in dollars per share)	$0.39	$0.47	$0.59
Diluted (in dollars per share)	$0.39	$0.46	$0.58
AVERAGE COMMON SHARES:	'	'	'
Basic (in shares)	42,607	42,176	39,086
Diluted (in shares)	42,884	42,610	39,733

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net income	$16,570	$19,710	$23,044
Unrealized gain (loss) on marketable securities:	'	'	'
Unrealized holding gain arising during the period, net of tax effect of $0, $215, $115	0	336	180
Less: reclassification adjustment for gains included in net income,	0	-516	0
Interest rate swap, net of tax effect of ($1,164), $696, $451	1,828	-1,093	-708
Foreign currency translation adjustment, net of tax effect of $5, $15, $44	297	-59	-182
Total other comprehensive income (loss)	2,125	-1,332	-710
Total comprehensive income	$18,695	$18,378	$22,334

CONSOLIDATED_STATEMENTS_OF_COM1

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Unrealized holding gain arising during the period, tax effect	$0	$215	$115
Reclassification adjustment for gains included in net income, tax effect	0	330	0
Interest rate swap, tax effect	-1,164	696	451
Foreign currency translation adjustment, tax effect	$5	$15	$44

CONSOLIDATED_STATEMENTS_OF_STO

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
In Thousands, except Share data, unless otherwise specified
Beginning balance at Dec. 31, 2010	$235,615	$67,091	$167,664	$860
Beginning balance, shares at Dec. 31, 2010	'	35,496,000	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Net income	23,044	'	23,044	'
Other comprehensive loss, net of tax	-710	'	'	-710
Excess tax benefits from stock-based compensation	3,122	3,122	'	'
Stock-based compensation expense	1,644	1,644	'	'
Issuance of common stock, net of offering costs	87,700	87,700	'	'
Issuance of common stock, net of offering costs, shares	'	5,520,000	'	'
Issuance of common stock under Employee Stock Purchase Plans	430	430	'	'
Issuance of common stock under Employee Stock Purchase Plans, shares	'	31,000	'	'
Options exercised	8,449	8,449	'	'
Options exercised, shares	'	1,099,000	'	'
Shares surrendered in exchange for payment of payroll tax liabilities	953	953	'	'
Shares surrendered in exchange for payment of payroll tax liabilities, shares	'	-60,000	'	'
Shares surrendered in exchange for the exercise of stock options	-1,252	-1,252	'	'
Shares surrendered in exchange for the exercise of stock options, shares	-78,000	-78,000	'	'
Ending balance at Dec. 31, 2011	357,089	166,231	190,708	150
Ending balance, shares at Dec. 31, 2011	'	42,008,000	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Net income	19,710	'	19,710	'
Other comprehensive loss, net of tax	-1,332	'	'	-1,332
Excess tax benefits from stock-based compensation	877	877	'	'
Stock-based compensation expense	1,917	1,917	'	'
Issuance of common stock under Employee Stock Purchase Plans	430	430	'	'
Issuance of common stock under Employee Stock Purchase Plans, shares	'	33,000	'	'
Options exercised	5,156	5,156	'	'
Options exercised, shares	'	610,000	'	'
Shares surrendered in exchange for payment of payroll tax liabilities	-439	-439	'	'
Shares surrendered in exchange for payment of payroll tax liabilities, shares	'	-31,000	'	'
Shares surrendered in exchange for the exercise of stock options	-1,831	-1,831	'	'
Shares surrendered in exchange for the exercise of stock options, shares	-131,000	-131,000	'	'
Ending balance at Dec. 31, 2012	381,577	172,341	210,418	-1,182
Ending balance, shares at Dec. 31, 2012	'	42,489,000	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'
Net income	16,570	'	16,570	'
Other comprehensive loss, net of tax	2,125	'	'	2,125
Excess tax benefits from stock-based compensation	259	259	'	'
Stock-based compensation expense	1,467	1,467	'	'
Issuance of common stock under Employee Stock Purchase Plans	448	448	'	'
Issuance of common stock under Employee Stock Purchase Plans, shares	'	37,000	'	'
Options exercised	3,733	3,733	'	'
Options exercised, shares	368,000	413,000	'	'
Shares surrendered in exchange for payment of payroll tax liabilities	-21	-21	'	'
Shares surrendered in exchange for payment of payroll tax liabilities, shares	'	-48,000	'	'
Shares surrendered in exchange for the exercise of stock options	-452	-452	'	'
Shares surrendered in exchange for the exercise of stock options, shares	-45,000	-45,000	'	'
Ending balance at Dec. 31, 2013	$405,706	$177,775	$226,988	$943
Ending balance, shares at Dec. 31, 2013	'	42,846,000	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net income	$16,570	$19,710	$23,044
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	32,542	22,534	19,194
Losses on sales and/or abandonment of property and equipment	177	204	31
Write-off of patents and intangible assets	8,208	55	103
Impairment of cost-method investment	0	2,368	0
Acquired in-process research and development	0	2,450	5,838
Amortization of deferred credits	-139	-174	-106
Amortization of long-term debt issuance costs	845	0	0
Realized gain on sale of marketable securities	0	-745	0
Deferred income taxes	1,359	549	1,677
Excess tax benefits from stock-based compensation	-259	-877	-3,122
Stock-based compensation expense	1,467	1,917	1,644
Changes in operating assets and liabilities, net of effects from acquisitions:	'	'	'
Trade receivables	-6,445	-6,576	-3,323
Employee receivables	-53	-11	-62
Other receivables	-609	-760	-245
Inventories	2,334	-8,965	-9,314
Prepaid expenses	-758	736	-1,726
Prepaid income taxes	18	-367	-431
Income tax refund receivables	1,267	452	-733
Other assets	-1,806	-1,178	-283
Trade payables	-5	7,721	-2,129
Accrued expenses	-276	4,448	1,334
Advances from employees	-277	317	-65
Income taxes payable	255	2,057	2,658
Liabilities related to unrecognized tax benefits	-520	-209	-226
Deferred compensation payable	1,877	1,371	327
Other long-term obligations	-4,399	-89	-70
Total adjustments	34,803	27,228	10,971
Net cash provided by operating activities	51,373	46,938	34,015
Capital expenditures for:	'	'	'
Property and equipment	-59,505	-64,643	-59,195
Intangible assets	-1,617	-1,460	-2,077
Proceeds from sale-leaseback transaction	24,000	0	0
Purchase of marketable securities	0	0	-2,503
Proceeds from the sale of marketable securities	0	3,248	0
Proceeds from the sale of property and equipment	113	43	5
Cash paid in acquisitions, net of cash acquired	-31,600	-192,762	-10,250
Net cash used in investing activities	-68,609	-255,574	-74,020
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Proceeds from issuance of common stock	3,729	3,755	95,454
Payment of offering costs related to issuance of common stock	0	0	-127
Proceeds from issuance of long-term debt	176,764	330,630	104,585
Payments on long-term debt	-165,477	-123,801	-155,386
Proceeds from industrial assistant grants	389	1,029	0
Excess tax benefits from stock-based compensation	259	877	3,122
Long-term debt issuance costs	-798	-3,706	0
Contingent payments related to acquisitions	-77	-57	0
Payment of taxes related to an exchange of common stock	-21	-439	-953
Net cash provided by financing activities	14,768	208,288	46,695
EFFECT OF EXCHANGE RATES ON CASH	208	-61	-297
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	-2,260	-409	6,393
CASH AND CASH EQUIVALENTS:	'	'	'
Beginning of year	9,719	10,128	3,735
End of year	7,459	9,719	10,128
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	'	'	'
Interest (net of capitalized interest of $1,038, $456 and $299, respectively)	7,877	434	509
Income taxes	735	5,277	7,023
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES	'	'	'
Property and equipment purchases in accounts payable	4,055	12,372	8,849
Acquisition of customer list in exchange for a settlement of trade receivables	0	377	0
Acquisition purchases in accrued expenses and other long-term obligations	350	5,149	1,270
Merit common stock surrendered (45, 131 and 78 shares, respectively) in exchange for exercise of stock options	$452	$1,831	$1,252

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Cash Flows [Abstract]	'	'	'
Net capitalized interest	$1,038	$456	$299
Company's common stock surrendered in exchange for the exercise of stock options (in shares)	45	131	78

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization and Summary of Significant Accounting Policies	'
	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Organization. Merit Medical Systems, Inc. (“Merit,” “we,” or “us”) designs, develops, manufactures and markets single-use medical products for interventional and diagnostic procedures. For financial reporting purposes, we report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology devices which assist in diagnosing and treating coronary arterial disease, peripheral vascular disease and other non-vascular diseases and includes the embolotherapeutic products and the cardiac rhythm management and electrophysiology ("CRM/EP") devices we acquired through our acquisition of Thomas Medical as described in Note 2 below. Our endoscopy segment consists of gastroenterology and pulmonology medical devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors.
	We manufacture our products in plants located in the United States, The Netherlands, Ireland and France. We export sales to dealers and have direct sales forces in the United States, Western Europe and China (see Note 12). Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The following is a summary of the more significant of such policies.
	Use of Estimates in Preparing Financial Statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
	Principles of Consolidation. The consolidated financial statements include our wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
	Cash and Cash Equivalents. For purposes of the statements of cash flows, we consider interest bearing deposits with an original maturity date of three months or less to be cash equivalents.
	Receivables. The allowance for uncollectible accounts receivable is based on our historical bad debt experience and on management’s evaluation of our ability to collect individual outstanding balances.
	Inventories. We value our inventories at the lower of cost, determined on a first-in, first-out method, or market value.  Market value for raw materials is based on replacement costs. Inventory costs include material, labor and manufacturing overhead.  We review inventories on hand at least quarterly and record provisions for estimated excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. The regular and systematic inventory valuation reviews include a current assessment of future product demand, historical experience and product expiration.
	Goodwill and Intangible Assets. We test goodwill balances as of July 1 for impairment on an annual basis during the third quarter, or whenever impairment indicators arise. We utilize several reporting units in evaluating goodwill for impairment. We assess the estimated fair value of reporting units using a combination of a market-based approach with a guideline public company method and a discounted cash flow methodology. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, an impairment charge is recognized in an amount equal to the excess of the carrying amount of the reporting unit goodwill over the implied fair value of that goodwill.
	We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:
	Customer lists	2	-	15 years
	Developed technology	5	-	15 years
	Distribution agreements	4	-	12 years
	License agreements and trademarks	5	-	15 years
	Covenant not to compete	3	-	10 years
	Patents	17 years
	Royalty agreements	5 years
	Long-Lived Assets. We periodically review the carrying amount of our long-lived assets for impairment. An asset is considered impaired when estimated future cash flows are less than the carrying amount of the asset. In the event the carrying amount of such asset is not considered recoverable, the asset is adjusted to its fair value. Fair value is generally determined based on discounted future cash flow. There were no impairments of long-lived assets during the years ended December 31, 2013, 2012 and 2011.
	Property and Equipment. Property and equipment is stated at the historical cost of construction or purchase. Construction costs include interest costs capitalized during construction. Maintenance and repairs of property and equipment are charged to operations as incurred. Leasehold improvements are amortized over the lesser of the base term of the lease or estimated life of the leasehold improvements. Construction-in-process consists of new buildings and various production equipment being constructed internally and externally. Assets in construction-in-process will commence depreciating once the asset has been placed in service. Depreciation is computed using the straight-line method over estimated useful lives as follows:
	Buildings	40 years
	Manufacturing equipment	4	-	20 years
	Furniture and fixtures	3	-	20 years
	Land improvements	10	-	20 years
	Leasehold improvements	4	-	25 years
	Depreciation expense related to property and equipment for the years ended December 31, 2013, 2012 and 2011 was approximately $18.4 million, $15.0 million, and $13.2 million, respectively.
	Deferred Compensation. We have a deferred compensation plan that permits certain management employees to defer a portion of their salary until the future. We established a Rabbi trust to finance obligations under the plan with corporate-owned variable life insurance contracts. The cash surrender value totaled approximately $7.8 million and $6.1 million at December 31, 2013 and 2012, respectively, which is included in other assets in our consolidated balance sheets. We have recorded a deferred compensation payable of approximately $7.8 million and $6.0 million at December 31, 2013 and 2012, respectively, to reflect the liability to our employees under this plan.
	Marketable Securities. Marketable securities consisted entirely of available-for-sale equity securities. As of December 31, 2011, these equity securities had a cost basis of approximately $2.5 million, fair value of approximately $2.8 million, and gross unrealized gains that were included in accumulated other comprehensive income of approximately $295,000. There were no marketable securities held as of December 31, 2013 or December 31, 2012.
	Other Assets. Other assets consist of our deferred compensation plan cash surrender value discussed above, unamortized debt issuance costs, two investments in privately-held companies accounted for at cost, a long-term income tax refund receivable, and deposits related to various leases.
	Deferred Credits. Deferred credits consist of grant money received from the Irish government. Grant money is received for a percentage of expenditures on eligible property and equipment, specific research and development projects and costs of hiring and training employees. Amounts related to the acquisition of property and equipment are amortized as a reduction of depreciation expense over the lives of the corresponding property and equipment.
	Revenue Recognition. We sell our single-use disposable medical products through a direct sales force in the U.S., through OEM relationships, custom procedure tray manufacturers and a combination of direct sales force and independent distributors in international markets. Revenues from these customers are recognized when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable and (iv) the ability to collect is reasonably assured. These criteria are generally satisfied at the time of shipment when risk of loss and title passes to the customer. We have certain written agreements with group purchasing organizations to sell our products to participating hospitals. These agreements have destination shipping terms which require us to defer the recognition of a sale until the product has arrived at the participating hospitals. We reserve for sales returns, including returns related to defective products (i.e. warranty liability), as a reduction in net sales, based on our historical experience. We also offer sales rebates and discounts to purchasing groups. These reserves are recorded as a reduction in net sales and are not considered material to our consolidated statements of income for the years ended December 31, 2013, 2012 and 2011. In addition, we invoice our customers for taxes assessed by governmental authorities such as sales tax and value added taxes. We present these taxes on a net basis.
	Shipping and Handling. We bill our customers for shipping and handling charges, which are included in net sales for the applicable period, and the corresponding shipping and handling expense is reported in cost of sales.
	Cost of Sales. We include product costs (i.e. material, direct labor and overhead costs), shipping and handling expense, product royalty expense, developed technology amortization expense, production-related depreciation expense and product license agreement expense in cost of sales.
	Research and Development. Research and development costs are expensed as incurred.
	Income Taxes. We utilize an asset and liability approach for financial accounting and reporting for income taxes. Deferred income taxes are provided for temporary differences in the basis of assets and liabilities as reported for financial statement and income tax purposes. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income for each full fiscal year.
	Earnings per Common Share. Net income per common share is computed by both the basic method, which uses the weighted average number of our common shares outstanding and the diluted method, which includes the dilutive common shares from stock options and warrants, as calculated using the treasury stock method.
	Fair Value Measurements. The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market-based inputs or inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
	Stock-Based Compensation. We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation — Stock Compensation. Under the provisions of ASC 718, share-based compensation cost is measured at the grant date, based on the fair value of the award and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model. Stock-based compensation expense for the years ended December 31, 2013, 2012 and 2011 was approximately $1.5 million, $1.9 million and $1.6 million, respectively.
	Concentration of Credit Risk. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We provide credit, in the normal course of business, primarily to hospitals and independent third-party custom procedure tray manufacturers and distributors. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses. Sales to our single largest customer approximated 3%, 4% and 4% of total sales for the years ended December 31, 2013, 2012 and 2011, respectively.
	Foreign Currency. The financial statements of our foreign subsidiaries are measured using local currencies as the functional currency, with the exception of Ireland which uses the U.S. Dollar as its functional currency. Assets and liabilities are translated into U.S. Dollars at year-end rates of exchange and results of operations are translated at average rates for the year. Gains and losses resulting from these translations are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Foreign currency transactions denominated in a currency other than the entity’s functional currency are included in determining net income for the period. Such foreign currency transaction gains and losses have not been significant for purposes of our financial reporting.
	Derivatives. We use forward contracts to mitigate our exposure to volatility in foreign exchange rates, and we used an interest rate swap to hedge changes in the benchmark interest rate related to our Credit Agreement described in Note 7 below. All derivatives are recognized in the consolidated balance sheets at fair value. Classification of each hedging instrument is based upon whether the maturity of the instrument is less than or greater than 12 months. We do not purchase or hold derivative financial instruments for speculative or trading purposes. See Note 8.
	Accumulated Other Comprehensive Income (Loss). As of December 31, 2013, accumulated other comprehensive income (loss) included approximately $735,000 (net of tax of $(468,000)) related to an interest rate swap and $208,000 (net of tax of $12,000) related to foreign currency translation. As of December 31, 2012, accumulated other comprehensive income (loss) included approximately $(1.1) million (net of tax of $696,000) related to an interest rate swap and ($89,000) (net of tax of $7,000) related to foreign currency translation.
	Recently Issued Financial Accounting Standards. In July 2013, the Financial Accounting Standards Board ("FASB"), issued authoritative guidance which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.
	In March 2013, the FASB issued amendments to address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a non-profit activity or a business within a foreign entity. The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted). The adoption of this guidance is not expected to have a material effect on our consolidated financial position or results of operations.
	In February 2013, the FASB issued amendments to disclosure requirements for presentation of comprehensive income. The standard requires presentation (either in a single note or parenthetically on the face of the financial statements) of the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, a cross reference to the related footnote for additional information is required. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this guidance did not have a material effect on our consolidated financial statements.
	In July 2012, the FASB issued authoritative guidance related to testing indefinite-lived intangible assets for impairment. This guidance simplifies how entities test indefinite-lived intangible assets for impairment and permits an entity to first assess qualitative factors to determine whether it is more likely than not that the indefinite-lived intangible asset is impaired. This guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Acquisitions	'
	ACQUISITIONS
	On December 20, 2013, we acquired a license agreement to sell our Hepasphere products in China. We paid $350,000 to purchase the license. We are obligated to pay an additional $350,000, which is included in accrued liabilities at December 31, 2013. The purchase price was allocated to a license agreement for $700,000, which we intend to amortize over four years.
	On October 4, 2013, we acquired certain assets contemplated by an Asset Purchase Agreement we executed with Datascope Corp. ("Datascope"), a Delaware corporation. The primary assets we acquired consist of the Safeguard® Pressure Assisted Device, which assists in obtaining and maintaining hemostasis after a femoral procedure, and the Air-Band™ Radial Compression Device, which is indicated to assist hemostasis of the radial artery puncture site while maintaining visibility. We accounted for this acquisition as a business combination. We made a payment of approximately $27.5 million to acquire these assets. Acquisition-related costs during the year ended December 31, 2013, which were included in selling, general, and administrative expenses in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2013, our net sales of Datascope products were approximately $1.6 million. It is not practical to separately report the earnings related to the Datascope acquisition, as we cannot split out sales costs related to Datascope products, principally because our sales representatives are selling multiple products (including Datascope products) in the cardiovascular business segment. The total purchase price was preliminarily allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	478
	Intangibles
	Developed technology	18,200
	Customer lists	390
	Trademarks	320
	Goodwill	8,112
	Total assets acquired	$	27,500
	With respect to the Datascope assets, we intend to amortize developed technology over 10 years and customer lists on an accelerated basis over six years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 10 years.
	On October 4, 2013, we acquired certain assets contemplated by an Asset Purchase Agreement with Radial Assist, LLC ("Radial Assist"), a Georgia limited liability company. The primary assets we acquired consist of the Rad Board®, Rad Board®Xtra™, Rad Trac™, and Rad Rest® devices. The Rad Board is designed to provide a larger work space for physicians and an area for patients to rest their arms during radial procedures. The Rad Board Xtra is designed to work in conjunction with the Rad Board by extending the usable work space and allowing for a 90-degree perpendicular extension of the arm for physicians who prefer doing procedures at a 90-degree angle. The Rad Trac is also designed to be used with the Rad Board and facilitates placement and removal of the Rad Board with the patient still on the table. The Rad Rest is a disposable, single-use product designed to stabilize the arm by ergonomically supporting the elbow, forearm and wrist during radial procedures. We accounted for this acquisition as a business combination. We made a payment of approximately $2.5 million to acquire these assets. Acquisition-related costs during the year ended December 31, 2013, which were included in selling, general, and administrative expenses in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2013, our net sales of Radial Assist products were approximately $191,000. It is not practical to separately report the earnings related to the Radial Assist acquisition, as we cannot split out sales costs related to Radial Assist products, principally because our sales representatives are selling multiple products (including Radial Assist products) in the cardiovascular business segment. The total purchase price was preliminarily allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	16
	Intangibles
	Developed technology	1,520
	Customer lists	20
	Trademarks	40
	Goodwill	904
	Total assets acquired	$	2,500
	With respect to the Radial Assist assets, we intend to amortize developed technology over 10 years and customer lists on an accelerated basis over six years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 10.07 years.
	In connection with our Datascope and Radial Assist acquisitions, we paid approximately $798,000 in long-term debt issuance costs to Wells Fargo Bank related to the amendment of our Credit Agreement (see Note 7). These costs consist primarily of loan origination fees that we intend to amortize over the remaining contract term of our Credit Agreement, which matures December 19, 2017.
	On September 10, 2013, we entered into a license agreement with a medical device company for the exclusive rights to sell certain biocompatible gloves, instrument cleaners, and surgical wipes. We paid $250,000 for the use of the license. We are obligated to pay an additional $250,000 within 30 days of our first commercial sale of the product. The purchase price was allocated to a license agreement for $250,000, which we intend to amortize over 10 years.
	On December 19, 2012, we consummated the transactions contemplated by a Stock Purchase Agreement with Vital Signs, Inc., an affiliate of GE Healthcare (“Vital Signs”), as seller, and purchased all of the issued and outstanding shares of Thomas Medical Products, Inc. (“Thomas Medical”), a Pennsylvania corporation. The primary assets of Thomas Medical are the various patents, trademarks, and business related to introducers, hemostatic valves, and sheaths. Using the splittable hemostatic introducer sheath as an entry product, we intend to develop a portfolio of premium accessories for electrophysiology physicians. We accounted for this acquisition as a business combination. We made an initial payment of $167.0 million to Vital Signs in December 2012. We also accrued an additional $445,000 at December 31, 2012, related to a final payment made to Vital Signs in February 2013 for net working capital received in excess of the target net working capital specified. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. Our consolidated financial statements for the year ended December 31, 2012 include approximately $1.9 million and $51,000 of net sales and income before tax, respectively, related to the Thomas Medical acquisition. The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Trade receivables	$	6,507
	Inventories	5,459
	Prepaid expenses	340
	Property and equipment	2,685
	Intangibles
	Developed technology	43,000
	Non-compete agreements	500
	Customer lists	5,000
	Trademarks	1,400
	Goodwill	102,407
	Total assets acquired	167,298
	Liabilities Assumed
	Trade payables	588
	Accrued expenses	1,094
	Total liabilities assumed	1,682
	Net assets acquired, net of cash acquired of $1,829	$	165,616
	During the year ended December 31, 2013, the goodwill related to the Thomas Medical acquisition was increased by approximately $381,000 due to an adjustment related to inventories.
	The gross amount of trade receivables we acquired in the Thomas Medical transaction was approximately $6.5 million, of which $34,000 was expected to be uncollectible. With respect to the Thomas Medical assets, we intend to amortize developed technology over eight years, customer lists on an accelerated basis over 12 years, and non-compete agreements over three years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 8.55 years.
	In connection with our Thomas Medical acquisition, we paid approximately $3.7 million in long-term debt issuance costs to Wells Fargo Bank related to our Credit Agreement (see Note 7). These costs consist primarily of loan origination fees that we intend to amortize over five years, which is the contract term of our Credit Agreement. We also incurred approximately $2.7 million of acquisition-related costs during the year ended December 31, 2012, which are included in selling, general and administrative expense in the accompanying consolidated statements of operations.
	On November 19, 2012, we entered into an Asset Purchase Agreement with Janin Group, Inc. (dba MediGroup) ("MediGroup"), an Illinois corporation, to purchase substantially all of the assets of MediGroup. The primary assets of MediGroup are the patented Flex-Neck® Peritoneal Dialysis Catheters and Y-TEC™ Peritoneal Dialysis Implantation Kits. We accounted for this acquisition as a business combination. We made an initial payment of approximately $4.0 million in November 2012. In addition, we are obligated to make contingent payments of up to $150,000 per year during 2013, 2014 and 2015. Furthermore, we are obligated to make contingent purchase price payments of $150,000 per year in 2016 through 2022 if net sales of Medigroup products increase at least 8% in each subsequent year. If net sales of MediGroup products have not increased by the percentage set forth in any year, our obligation to make these contingent payments shall cease. The acquisition-date fair value of the contingent consideration liability of approximately $403,000 was included as part of the purchase consideration. Acquisition-related costs during the year ended December 31, 2012, which are included in selling, general, and administrative expense in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2012, our net sales of MediGroup products were approximately $169,000. It is not practical to separately report the earnings related to the MediGroup acquisition, as we cannot split out sales costs related to MediGroup products, principally because our sales representatives are selling multiple products (including MediGroup products) in the cardiovascular business segment. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	263
	Property and equipment	79
	Intangibles
	Developed technology	2,000
	Non-compete agreements	210
	Customer lists	110
	Trademarks	80
	Goodwill	1,697
	Total assets acquired	$	4,439
	With respect to the MediGroup assets, we intend to amortize developed technology over eight years, customer lists on an accelerated basis over eight years, and non-compete agreements over seven years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 8.15 years.
	On August 27, 2012, we entered into a license agreement with a medical device company for the use of certain patents. We paid $750,000 for the use of the license. The purchase price was allocated to a license agreement for $750,000, which we intend to amortize over three years.
	On August 21, 2012, we entered into a distribution and patent sublicense agreement with Catheter Connections, Inc. ("CathConn"), a Utah corporation, for the exclusive rights to sell certain disinfecting cap technologies. We paid CathConn $250,000 in August 2012 for the exclusive rights to distribute CathConn's MaleCap Solo technology in the field of interventional radiology and interventional cardiology. We can elect to pay an additional $250,000 for each of the exclusive rights to other aspects of CathConn's DualCap disinfecting cap technology. The purchase price was allocated to a distribution agreement for $250,000, which we intend to amortize over 10 years.
	On August 7, 2012, we purchased 422,594 special membership units, which represents an ownership interest of approximately 11.9%, of Blockade Medical LLC ("Blockade"), a Delaware limited liability company, for an aggregate price of approximately $1.0 million, which is accounted for at cost. Blockade develops, markets and sells catheter-based therapeutic devices.
	On January 31, 2012, we consummated the transactions contemplated by an Asset Purchase Agreement with Ostial Solutions, LLC ("Ostial"), a Michigan limited liability company, to purchase substantially all of the assets of Ostial. The primary asset of Ostial is the patented Ostial PRO Stent Positioning System, which is designed to facilitate precise stent implantation in coronary and renal aorto-ostial lesions. We accounted for this acquisition as a business combination. We made an initial payment of $10.0 million to Ostial in January 2012 and an additional payment of $6.5 million to Ostial in August 2012. In addition, we are obligated to make contingent purchase price payments of up to $13.5 million based on a percentage of future sales of products utilizing the Ostial PRO Stent Positioning System. The acquisition-date fair value of this contingent consideration liability of $4.3 million was included as part of the purchase consideration and was determined using a discounted cash flow model based upon the expected timing and amount of these future contingent payments. Acquisition-related costs during the year ended December 31, 2012, which are included in selling, general, and administrative expense in the accompanying consolidated statements of income, were not material. The results of operations related to this acquisition have been included in our cardiovascular segment since the acquisition date. During the year ended December 31, 2012, our net sales of products utilizing the Ostial PRO Stent Positioning System were approximately $457,000. It is not practical to separately report the earnings related to the Ostial acquisition, as we cannot split out sales costs related to Ostial products, principally because our sales representatives are selling multiple products (including Ostial products) in the cardiovascular business segment. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Intangibles
Developed technology	$	10,500
Customer lists	600
Trademark	110
Non-compete agreements	10
Goodwill	9,580
Total assets acquired	$	20,800
With respect to the Ostial assets, we intend to amortize developed technology over 15 years, customer lists on an accelerated basis over eight years, and non-compete agreements over five years. While U.S. trademarks can be renewed indefinitely, we currently estimate that we will generate cash flow from the acquired trademarks for a period of 15 years from the acquisition date. The total weighted-average amortization period for these acquired intangible assets is 14.6 years.
The following table summarizes our unaudited consolidated results of operations for the years ended December 31, 2013, 2012 and 2011, as well as unaudited pro forma consolidated results of operations as though the Thomas Medical, MediGroup, and Ostial acquisitions had occurred on January 1, 2011 and the Datascope acquisition had occurred on January 1, 2012 (in thousands, except per common share amounts):
	2013				2012				2011
	As Reported		Pro Forma		As Reported		Pro Forma		As Reported		Pro Forma
Net sales	$	449,049	$	454,333	$	394,288	$	438,981	$	359,449	$	396,767
Net income	16,570		17,112		19,710		25,075		23,044		22,033
Earnings per common share:
Basic	$	0.39	$	0.4	$	0.47	$	0.59	$	0.59	$	0.56
Diluted	$	0.39	$	0.4	$	0.46	$	0.59	$	0.58	$	0.55
The unaudited pro forma information set forth above is for informational purposes only and includes adjustments related to the step-up of acquired inventories, amortization expense related to acquired intangible assets, and interest expense on long-term debt. The pro forma information should not be considered indicative of actual results that would have been achieved if the Thomas Medical, MediGroup, and Ostial acquisitions had occurred on January 1, 2011 and the Datascope acquisition had occurred on January 1, 2012, or results that may be obtained in any future period. The pro forma consolidated results of operations do not include the Radial Assist acquisition, as we do not deem the pro forma effect of the transaction to be material.
On January 5, 2012, we entered into a Marketing and Distribution Agreement with Scion Cardio-Vascular, Inc. (“Scion”), a Florida corporation, wherein we purchased the exclusive, worldwide right to distribute the Clo-SurPLUS P.A.D.™ for $2.5 million. We made an initial payment of $1.5 million to Scion in January 2012. We made an additional payment of $1.0 million in May 2012 upon reaching a milestone set forth in the purchase agreement. The purchase price was allocated to a distribution agreement for $2.5 million, which we intend to amortize over 12 years. As a result of entering into this agreement, we terminated several exclusive Scion sales distributor agreements where we had previously established direct sales relationships. In connection with the termination of these agreements, we agreed to purchase customer lists from the terminated distributors. The total purchase price of the customer lists was approximately $95,000 and was allocated to other intangible assets in the accompanying consolidated balance sheet as of December 31, 2012. We intend to amortize the customer lists on an accelerated basis over five years.
During the year ended December 31, 2012, we purchased several patents for the development of future products. A total charge of approximately $2.5 million related to these asset acquisitions has been recorded to acquired in-process research and development in the accompanying consolidated statements of income for the year ended December 31, 2012, as both technological feasibility of the underlying research and development projects had not yet been reached and such technology had no future alternative use as of the respective date of each asset acquisition.
On September 2, 2011, we entered into an Asset Purchase Agreement with Ash Access Technology, Inc. (“Ash Access”), an Indiana corporation, and AAT Catheter Technologies, LLC (“AAT”), an Indiana limited liability corporation (collectively “Ash”), to purchase intellectual property rights with respect to various dialysis catheters. We accounted for this acquisition as a business combination. We made an initial payment of $5.0 million to Ash in September 2011. We are obligated to pay an additional $1.0 million upon reaching a milestone set forth in the purchase agreement and future royalties based on a percentage of related product sales. The acquisition-date fair value of the contingent consideration liability of approximately $1.3 million was included as part of the purchase consideration. Acquisition-related costs during the year ended December 31, 2011, respectively, which are included in selling, general and administrative expense in the accompanying consolidated statements of operations, were not material. During the year ended December 31, 2011, net sales subsequent to the acquisition date related to our dialysis catheter acquired were not material. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
Assets Acquired
Property and equipment	$	73
Intangibles
Developed technology	3,200
Customer lists	300
Goodwill	2,697
Total assets acquired	$	6,270
During the year ended December 31, 2012, the goodwill related to the Ash acquisition was increased by approximately $280,000 due to adjustments to the contingent consideration liability.
With respect to the assets we acquired from Ash, we intend to amortize developed technology over 15 years and customer lists on an accelerated basis over two years. The total weighted-average amortization period for these acquired intangible assets is nine years. The assets and liabilities related to this acquisition are included in our cardiovascular segment.
Pro forma consolidated financial results for the Ash acquisition discussed above have not been included in our consolidated financial results because we believe their effects would not be material.
On July 18, 2011, we acquired the intellectual property rights to certain introducer sheath technology. We made an initial payment of $1.0 million in July 2011, and we are obligated to pay an additional $1.0 million upon the earlier of the commercialization of the product or the third anniversary of the effective date of the agreement. The discounted liabilities of $989,000 and $968,000 have been reflected in our consolidated balance sheets in accrued expenses as of December 31, 2013 and as long-term liabilities as of December 31, 2012, respectively.
On June 20, 2011, we acquired the intellectual property rights to certain vena cava filter technology. We made an initial payment of $1.0 million in June 2011, and we are obligated to pay up to an additional $3.5 million if certain milestones set forth in the agreement are reached related to further research and development activities and regulatory approval of the vena cava filter.
On December 15, 2011, we acquired the intellectual property rights to certain support guide catheter technology. We made an initial payment of $2.0 million in December 2011 and a payment of $1.0 million in May 2012 based on an obligation set forth in the agreement having been met. We paid an additional $1.0 million in January 2013 due to the completion of certain milestones related to regulatory approval of the support guide catheter.
The vena cava filter technology, introducer sheath technology, and support guide technology discussed above represented asset acquisitions related to a research and development project and not business combinations. A total charge of approximately $4.9 million related to these acquired in-process research and development assets has been included in the accompanying consolidated statements of operations for the year ended December 31, 2011, as both technological feasibility of the underlying research and development projects had not yet been reached and such technology had no future alternative use as of the respective date of each asset acquisition. During the year ended December 31, 2011, we also abandoned the development of certain biomaterial technology and our covered biliary in-process research and development, resulting in charges of $500,000 and $400,000, respectively.
On April 6, 2011, we acquired the manufacturing rights for certain valve technology. We made an initial payment of $500,000 in April 2011 and a final payment of $500,000 in August 2011. We recorded the $1.0 million intangible asset as developed technology for purposes of our consolidated balance sheet and we intend to amortize it over an estimated life of ten years.
The goodwill arising from the acquisitions discussed above consists largely of the synergies and economies of scale we hope to achieve from combining the acquired assets and operations with our historical operations (see Note 4). The goodwill recognized from these acquisitions is expected to be deductible for income tax purposes.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	Inventories at December 31, 2013 and 2012, consisted of the following (in thousands):
		2013		2012
	Finished goods	$	43,364	$	48,233
	Work-in-process	6,222		6,051
	Raw materials	32,792		30,315
	Total	$	82,378	$	84,599

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	GOODWILL AND INTANGIBLE ASSETS
	The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012, are as follows (in thousands):
		2013		2012
	Goodwill balance at January 1	$	175,108	$	61,144
	Adjustment related to previous acquisitions	381		280
	Additions as the result of acquisitions	9,016		113,684
	Goodwill balance at December 31	$	184,505	$	175,108
	As of December 31, 2013, we have recorded $8.3 million of accumulated goodwill impairment charges.
	Other intangible assets at December 31, 2013 and 2012, consisted of the following (in thousands):
		2013
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Patents	$	9,302	$	(2,374	)	$	6,928
	Distribution agreements	5,176		(1,780		)	3,396
	License agreements	3,783		(1,249		)	2,534
	Trademarks	7,622		(1,844		)	5,778
	Covenants not to compete	1,029		(399		)	630
	Customer lists	20,626		(10,957		)	9,669
	Royalty agreements	267		(267		)	—
	Total	$	47,805	$	(18,870	)	$	28,935
		2012
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Patents	$	7,843	$	(2,045	)	$	5,798
	Distribution agreements	5,176		(1,301		)	3,875
	License agreements	2,733		(861		)	1,872
	Trademarks	7,311		(1,362		)	5,949
	Covenants not to compete	1,035		(160		)	875
	Customer lists	20,468		(8,038		)	12,430
	Royalty agreements	267		(267		)	—
	Total	$	44,833	$	(14,034	)	$	30,799
	Aggregate amortization expense for the years ended December 31, 2013, 2012 and 2011 was approximately $14.2 million, $7.5 million and $6.0 million, respectively.
	We evaluate long-lived assets, including amortizing intangible assets, for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. We perform the impairment analysis at the asset group for which the lowest level of identifiable cash flows are largely independent of the cash flows of other assets and liabilities. We compared the carrying value of the amortizing intangible assets acquired in our January 2012 acquisition of Ostial to the undiscounted cash flows expected to result from the asset group and determined that the carrying amount was not recoverable. We then determined the fair value of the amortizing assets related to the Ostial acquisition based on estimated future cash flows discounted back to their present value using a discount rate that reflects the risk profiles of the underlying activities. Some of the factors that influenced our estimated cash flows were slower than anticipated sales growth in the products acquired from our Ostial acquisition and uncertainty about future sales growth. The excess of the carrying value compared to the fair value was recognized as an intangible asset impairment charge. During the third quarter of 2013, we recorded an impairment charge of approximately $8.1 million, which was offset by approximately $3.8 million of fair value reductions to the related contingent consideration liability.
	Estimated amortization expense for the intangible assets for the next five years consists of the following as of December 31, 2013 (in thousands):
	Year Ending December 31
	2014	$	15,189
	2015	14,751
	2016	14,094
	2017	13,678
	2018	13,158

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	INCOME TAXES
	For the years ended December 31, 2013, 2012 and 2011, income before income taxes is broken out between U.S. and foreign-sourced operations and consisted of the following (in thousands):
		2013			2012			2011
	Domestic	$	5,435		$	15,958		$	21,123
	Foreign	14,404			11,660			11,752
	Total	$	19,839		$	27,618		$	32,875
	The components of the provision for income taxes for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013			2012			2011
	Current expense (benefit):
	Federal	$	(747	)	$	5,350		$	5,662
	State	333			1,014			1,001
	Foreign	2,324			995			1,491
	Total current expense	1,910			7,359			8,154
	Deferred expense (benefit):
	Federal	1,089			871			1,121
	State	278			(343		)	74
	Foreign	(8		)	21			482
	Total deferred expense	1,359			549			1,677
	Total	$	3,269		$	7,908		$	9,831
	The difference between the income tax expense reported and amounts computed by applying the statutory federal rate of 35.0% to pretax income for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013			2012			2011
	Computed federal income tax expense at statutory rate of 35%	$	6,943		$	9,667		$	11,506
	State income taxes	397			436			699
	Tax credits	(1,385		)	(779		)	(778		)
	Production activity deduction	—			(388		)	(425		)
	Foreign tax rate differential	(2,374		)	(1,419		)	(1,297		)
	Uncertain tax positions	(520		)	(42		)	281
	Deferred compensation insurance assets	(358		)	(155		)	88
	Other — including the effect of graduated rates	566			588			(243		)
	Total income tax expense	$	3,269		$	7,908		$	9,831
	Deferred income tax assets and liabilities at December 31, 2013 and 2012, consisted of the following temporary differences and carry-forward items (in thousands):
		2013			2012
	Deferred income tax assets:
	Allowance for uncollectible accounts receivable	$	342		$	348
	Accrued compensation expense	5,001			3,954
	Inventory differences	2,317			1,949
	Net operating loss carry-forwards	18,060			19,622
	Deferred revenue	280			237
	Stock-based compensation expense	2,704			2,465
	Uncertain tax positions	559			709
	Federal research and development credit carry-forward	569			—
	Other	3,197			3,762
	Total deferred income tax assets	33,029			33,046
	Deferred income tax liabilities:
	Prepaid expenses	(751		)	(757		)
	Property and equipment	(21,893		)	(19,001		)
	Intangible assets	(3,837		)	(4,107		)
	Other	(1,295		)	(1,116		)
	Total deferred income tax liabilities	(27,776		)	(24,981		)
	Valuation allowance	(1,363		)	(1,225		)
	Net deferred income tax assets	$	3,890		$	6,840
	Reported as:
	Deferred income tax assets - Current	$	5,638		$	4,976
	Deferred income tax assets - Long-term	800			4,237
	Deferred income tax liabilities - Current	—			—
	Deferred income tax liabilities - Long-term	(2,548		)	(2,373		)
	Net deferred income tax assets	$	3,890		$	6,840
	The long-term deferred income tax balances are not netted as they represent deferred amounts applicable to different taxing jurisdictions. Deferred income tax balances reflect the temporary differences between the carrying amounts of assets and liabilities and their tax bases and are stated at enacted tax rates expected to be in effect when taxes are actually paid or recovered. The valuation allowance is primarily related to state credit carryforwards and capital losses for which we believe it is more likely than not that the deferred tax assets will not be realized. The valuation allowance increased by approximately $138,000, $864,000, and $361,000 during the years ended December 31, 2013, 2012 and 2011, respectively.
	We have not provided U.S. deferred income taxes or foreign withholding taxes on the undistributed earnings of certain foreign subsidiaries that are intended to be reinvested indefinitely in operations outside the United States. It is not practical to estimate the amount of additional taxes that might be payable on such undistributed earnings.
	As of December 31, 2013 and 2012, we had U.S federal net operating loss carryforwards of approximately $52.2 million and $56.0 million, respectively. These net operating loss carryforwards, which expire at various dates through 2030, are subject to an annual limitation under Internal Revenue Code Section 382. We anticipate that we will utilize the net operating loss carryforwards over the next 13 years. We utilized a total of approximately $3.8 million and $8.6 million in U.S. federal net operating loss carryforwards during the year ended December 31, 2013 and 2012, respectively.
	As of December 31, 2013 and 2012, we had non-U.S. net operating loss carryforwards of approximately $125,000 and $150,000, respectively, which have no expiration date. Non-U.S. net operating loss carryforwards utilized during 2013 and 2012 were not material.
	On January 2, 2013, the American Taxpayer Relief Act of 2012, which includes a reinstatement of the federal research and development credit for the tax year ended December 31, 2012, was signed into law. As a result, we recognized the retroactive benefit of the federal research and development credit of approximately $600,000 in 2013, the year in which the reinstatement was enacted.
	We are subject to income taxes in the United States and numerous foreign jurisdictions. Significant judgment is required in determining our worldwide provision for income taxes and recording the related assets and liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. In our opinion, we have made adequate provisions for income taxes for all years subject to audit. We are no longer subject to U.S. federal, state, and local income tax examinations by tax authorities for years before 2010. In foreign jurisdictions, we are no longer subject to income tax examinations for years before 2007.
Although we believe our estimates are reasonable, the final outcomes of these matters may be different from those which we have reflected in our historical income tax provisions and accruals. Such differences could have a material effect on our income tax provision and operating results in the period in which we make such determination.
The total liability for unrecognized tax benefits at December 31, 2013, including interest and penalties, was approximately $2.3 million, of which approximately $1.7 million would favorably impact our effective tax rate if recognized. Approximately $236,000 of the total liability at December 31, 2013 was presented as a reduction to non-current deferred income tax assets on our consolidated balance sheet as of that date. The total liability for unrecognized tax benefits at December 31, 2012, including interest and penalties, was approximately $2.9 million, of which approximately $2.2 million would favorably impact our effective tax rate if recognized. As of December 31, 2013 and 2012, we had accrued approximately $139,000 and $161,000 respectively, in total interest and penalties related to unrecognized tax benefits. We account for interest and penalties for unrecognized tax benefits as part of our income tax provision. During the years ended December 31, 2013 and 2012, we removed interest and penalties of approximately $22,000 and $215,000, respectively, from our liability for unrecognized tax benefits. The decrease in interest and penalties during 2012 was primarily related to an interest payment to the IRS in order to settle a withholding tax issue related to our acquisition of BioSphere. During the year ended December 31, 2011, we added interest and penalties of approximately $12,000 to our liability for unrecognized tax benefits. We anticipate the total liability for unrecognized tax benefits may be reduced, net of potential increases and decreases due to the expiration of statutes of limitation, by a range of approximately $200,000 to $600,000 within the next 12 months.
A reconciliation of the beginning and ending amount of liabilities associated with uncertain tax benefits for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
Tabular Roll-forward	2013			2012			2011
Unrecognized tax benefits, opening balance	$	2,776		$	3,113		$	2,952
Gross increases in tax positions taken in a prior year	107			83			347
Gross increases in tax positions taken in the current year	236			260			865
Settlements with taxing authorities	—			—			(507		)
Lapse of applicable statute of limitations	(990		)	(680		)	(544		)
Unrecognized tax benefits, ending balance	$	2,129		$	2,776		$	3,113
The tabular roll-forward ending balance does not include interest and penalties related to unrecognized tax benefits. During the year ended December 31, 2011, we paid approximately $507,000 to the IRS in order to settle a withholding tax issue related to an acquisition. The payment of the withholding tax did not have a material impact on our consolidated financial statements for the year ended December 31, 2011, as the tax liability had been identified as part of our acquisition accounting of BioSphere and recorded in our consolidated financial statements.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	ACCRUED EXPENSES
	Accrued expenses at December 31, 2013 and 2012, consisted of the following (in thousands):
		2013		2012
	Payroll taxes	$	1,816	$	1,893
	Payroll	3,474		3,141
	Bonuses	5,273		5,778
	Commissions	984		894
	Vacation	6,280		5,066
	Royalties	1,221		1,368
	Value-added tax	1,469		1,158
	Other accrued expenses	7,185		7,971
	Total	$	27,702	$	27,269

Revolving_Credit_Facility_and_

Revolving Credit Facility and Long-Term Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Revolving Credit Facility and Long-Term Debt	'
	REVOLVING CREDIT FACILITY AND LONG-TERM DEBT
	We entered into an Amended and Restated Credit Agreement, dated December 19, 2012, with the lenders who are or may become party thereto (collectively, the "Lenders") and Wells Fargo Bank, National Association ("Wells Fargo"), as administrative agent for the Lenders, which was amended on October 4, 2013 by a First Amendment to the Amended and Restated Credit Agreement by and among Merit, certain subsidiaries of Merit, the Lenders and Wells Fargo as administrative agent for the Lenders (as amended, the "Credit Agreement"). Pursuant to the terms of the Credit Agreement, the Lenders have agreed to make revolving credit loans up to an aggregate amount of $215 million. The Lenders also made a term loan in the amount of $100 million, repayable in quarterly installments in the amounts provided in the Credit Agreement until the maturity date of December 19, 2017, at which time the term and revolving credit loans, together with accrued interest thereon, will be due and payable. In addition, certain mandatory prepayments are required to be made upon the occurrence of certain events described in the Credit Agreement. Wells Fargo has agreed, upon satisfaction of certain conditions, to make swingline loans from time to time through the maturity date in amounts equal to the difference between the amounts actually loaned by the Lenders and the aggregate revolving credit commitment. The Credit Agreement is collateralized by substantially all of our assets. At any time prior to the maturity date, we may repay any amounts owing under all revolving credit loans, term loans, and all swingline loans in whole or in part, subject to certain minimum thresholds, without premium or penalty, other than breakage costs.
	The term loan and any revolving credit loans made under the Credit Agreement bear interest, at our election, at either (i) the base rate (described below) plus 0.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1), (ii) the London Inter-Bank Offered Rate (“LIBOR”) Market Index Rate (as defined in the Credit Agreement) plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1), or (iii) the LIBOR Rate (as defined in the Credit Agreement) plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1). Initially, the term loan and revolving credit loans under the Credit Agreement bear interest, at our election, at either (x) the base rate plus 1.00%, (y) the LIBOR Market Index Rate, plus 2.00%, or (z) the LIBOR Rate plus 2.00%. Swingline loans bear interest at the LIBOR Market Index Rate plus 1.25% (subject to adjustment if the Consolidated Total Leverage Ratio, as defined in the Credit Agreement, is at or greater than 2.25 to 1). Initially, swingline loans bear interest at the LIBOR Market Index Rate plus 2.00%. Interest on each loan featuring the base rate or the LIBOR Market Index Rate is due and payable on the last business day of each calendar month; interest on each loan featuring the LIBOR Rate is due and payable on the last day of each interest period selected by us when selecting the LIBOR Rate as the benchmark for interest calculation. For purposes of the Credit Agreement, the base rate means the highest of (i) the prime rate (as announced by Wells Fargo), (ii) the federal funds rate plus 0.50%, and (iii) LIBOR for an interest period of one month plus 1.00%. Our obligations under the Credit Agreement and all loans made thereunder are fully secured by a security interest in our assets pursuant to a separate collateral agreement entered into in conjunction with the Credit Agreement.
	The Credit Agreement contains customary covenants, representations and warranties and other terms customary for revolving credit loans of this nature. In this regard, the Credit Agreement requires us to not, among other things, (a) permit the Consolidated Total Leverage Ratio (as defined in the Credit Agreement) to be greater than 4.75 to 1 through the end of 2013, no more than 4.00 to 1 as of the fiscal quarter ending March 31, 2014, no more than 3.75 to 1 as of the fiscal quarter ending June 30, 2014, no more than 3.50 to 1 as of the fiscal quarter ending September 30, 2014, no more than 3.25 to 1 as of the fiscal quarter ending December 31, 2014, no more than 3.00 to 1 as of any fiscal quarter ending during 2015, no more than 2.75 to 1 as of any fiscal quarter ending during 2016, and no more than 2.50 to 1 as of any fiscal quarter ending thereafter; (b) for any period of four consecutive fiscal quarters, permit the ratio of Consolidated EBITDA (as defined in the Credit Agreement and subject to certain adjustments) to Consolidated Fixed Charges (as defined in the Credit Agreement) to be less than 1.75 to 1; (c) subject to certain adjustments, permit Consolidated Net Income (as defined in the Credit Agreement) for certain periods to be less than $0; or (d) subject to certain conditions and adjustments, permit the aggregate amount of all Facility Capital Expenditures (as defined in the Credit Agreement) in any fiscal year beginning in 2013 to exceed $30 million. Additionally, the Credit Agreement contains various negative covenants with which we must comply, including, but not limited to, limitations respecting: the incurrence of indebtedness, the creation of liens or pledges on our assets, mergers or similar combinations or liquidations, asset dispositions, the repurchase or redemption of equity interests or debt, the issuance of equity, the payment of dividends and certain distributions, the entry into related party transactions and other provisions customary in similar types of agreements. As of December 31, 2013, we were in compliance with all covenants set forth in the Credit Agreement.
	We had originally entered into an unsecured credit agreement, dated September 30, 2010, with certain lenders who were or became party thereto and Wells Fargo, as administrative agent for the lenders. Pursuant to the terms of that credit agreement, the lenders agreed to make revolving credit loans up to an aggregate amount of $125 million. Wells Fargo also agreed to make swingline loans from time to time through the maturity date of September 10, 2015 in amounts equal to the difference between the amount actually loaned by the lenders and the aggregate credit agreement. The unsecured credit agreement was amended and restated as of December 19, 2012, as the Credit Agreement.
	In summary, principal balances under our long-term debt as of December 31, 2013 and 2012, consisted of the following (in thousands):
		2013			2012
	Term loan	$	92,500		$	100,000
	Revolving credit loans	156,354			137,566
	Total long-term debt	248,854			237,566
	Less current portion	10,000			10,000
	Long-term portion	$	238,854		$	227,566
	Future minimum principal payments on our long-term debt as of December 31, 2013, are as follows (in thousands):
	Years Ending		Future Minimum
	December 31		Principal Payments
	2014		$	10,000
	2015		10,000
	2016		10,000
	2017		218,854
	Total future minimum principal payments		$	248,854
	As of December 31, 2013, we had outstanding borrowings of approximately $248.9 million under the Credit Agreement, with available borrowings of approximately $34.6 million, based on the leverage ratio in the terms of the Credit Agreement. Our interest rate as of December 31, 2013 was a fixed rate of 4.23% on $145.0 million as a result of an interest rate swap (see Note 8), a variable floating rate of 3.42% on $101.5 million and a variable floating rate of 3.50% on approximately $2.4 million. Our interest rate as of December 31, 2012 was a fixed rate of 2.98% on $150.0 million as a result of an interest rate swap, variable floating rate of 2.22% on $87.0 million and a variable floating rate of 2.31% on approximately $566,000.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives	'
	DERIVATIVES
	General. Our earnings and cash flows are subject to fluctuations due to changes in interest rates and foreign currency exchange rates, and we seek to mitigate a portion of these risks by entering into derivative contracts. The derivatives we use are an interest rate swap and forward contracts. We recognize derivatives as either assets or liabilities at fair value in the accompanying consolidated balance sheets, regardless of whether or not hedge accounting is applied. We report cash flows arising from our hedging instruments consistent with the classification of cash flows from the underlying hedged items. Accordingly, cash flows associated with our derivative programs are classified as operating activities in the accompanying consolidated statements of cash flows.
	We formally document, designate and assess the effectiveness of transactions that receive hedge accounting initially and on an ongoing basis. Changes in the fair value of derivatives that qualify for hedge accounting treatment are recorded, net of applicable taxes, in accumulated other comprehensive income (loss), a component of stockholders’ equity in the accompanying consolidated balance sheets. For the ineffective portions of qualifying hedges, the change in fair value is recorded through earnings in the period of change. Changes in the fair value of derivatives not designated as cash flow hedges are recorded in earnings throughout the term of the derivative instrument.
	Interest Rate Swap. A portion of our debt bears interest at variable interest rates and therefore, we are subject to variability in the cash paid for interest expense. In order to mitigate a portion of this risk, we use a hedging strategy to reduce the variability of cash flows in the interest payments associated with a portion of the variable-rate debt outstanding under our Credit Agreement that is solely due to changes in the benchmark interest rate.
	On December 19, 2012, we entered into a pay-fixed, receive-variable interest rate swap having an initial notional amount of $150 million with Wells Fargo to fix the one-month LIBOR rate at 0.98%. The variable portion of the interest rate swap is tied to the one-month LIBOR rate (the benchmark interest rate). The interest rates under both the interest rate swap and the underlying debt reset, the swap is settled with the counterparty, and interest is paid, on a monthly basis. The notional amount of the interest rate swap is reduced quarterly by 50% of the minimum principal payment due under the terms of the Credit Agreement. The interest rate swap is scheduled to expire on December 19, 2017.
	At December 31, 2013 and 2012, our interest rate swap qualified as a cash flow hedge. The fair value of our interest rate swap at December 31, 2013 was an asset of approximately $1.2 million, which was offset by approximately $468,000 in deferred taxes. The fair value of our interest rate swap at December 31, 2012 was a liability of approximately $1.8 million, which was offset by approximately $696,000 in deferred taxes.
	During the year ended December 31, 2011, we terminated a $55 million pay-fixed receive-variable interest rate swap agreement, which resulted in a cash receipt and gain of approximately $28,000 upon final settlement.
	During the years ended December 31, 2013, 2012 and 2011, the amount reclassified from accumulated other comprehensive income to earnings due to hedge effectiveness were included in interest expense in the accompanying consolidated statements of income and were not material.
	Foreign Currency Forward Contracts. On November 29, 2013, we forecasted a net exposure for December 31, 2013 (representing the difference between Euro and GBP-denominated receivables and Euro-denominated payables) of approximately 494,000 Euros and 847,000 GBPs. In order to partially offset such risks at November 29, 2013, we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 494,000 Euros and notional amount of 847,000 GBPs. On November 30, 2012, we forecasted a net exposure for December 31, 2012 (representing the difference between Euro and GBP-denominated receivables and Euro-denominated payables) of approximately 527,000 Euros and 565,000 GBPs. In order to partially offset such risks at November 30, 2012, we entered into a 30-day forward contract for the Euro and GBP with a notional amount of approximately 527,000 Euros and notional amount of 565,000 GBPs. We enter into similar transactions at various times during the year to partially offset exchange rate risks we bear throughout the year. These contracts are marked to market at each month-end. During the years ended December 31, 2013, 2012 and 2011, we recorded a net gain (loss) on all foreign currency transactions of approximately $(202,000), $(11,000) and $221,000, respectively, which is included in other income in the accompanying consolidated statements of income. The fair value of our open positions at December 31, 2013 and 2012 was not material.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	We are obligated under non-terminable operating leases for manufacturing facilities, finished good distribution, office space and equipment. Total rental expense on these operating leases and on our manufacturing and office building for the years ended December 31, 2013, 2012 and 2011, approximated $5.5 million, $4.8 million and $4.1 million, respectively.
	The future minimum lease payments for operating leases as of December 31, 2013, consisted of the following (in thousands):
	Years Ending	Operating
	December 31	Leases
	2014	$	6,569
	2015	5,956
	2016	4,974
	2017	4,122
	2018	4,073
	Thereafter	36,067
	Total minimum lease payments	$	61,761
	Sale-Leaseback. During the fourth quarter of 2013, we entered into a sale and leaseback transaction with a third-party lessor for the sale and leaseback of our Pearland, Texas facility for $24.0 million. The lease agreement from this sale and leaseback transaction is accounted for as an operating lease. Under the terms of the lease agreement, we will continue to operate and maintain the building. The lease term is 19.8 years. Payments under the lease agreement are fixed. The lease agreement contains standard termination events, including termination upon a breach of our obligation to make rental payments and upon any other material breach of obligations under the lease, and standard maintenance and return condition provisions.
	Irish Government Development Agency Grants. As of December 31, 2013, we had entered into several grant agreements with the Irish Government Development Agency. We have recorded the grants related to research and development projects and costs of hiring and training employees as a reduction of operating expenses for the years ended December 31, 2013, 2012 and 2011 in the amounts of approximately $1.2 million, $424,000 and $261,000, respectively. Grants related to the acquisition of property and equipment purchased in Ireland are amortized as a reduction to depreciation expense over lives corresponding to the depreciable lives of such property and equipment. The balance of deferred credits related to such grants as of December 31, 2013 and 2012, was approximately $3.1 million and $3.0 million, respectively. During the years ended December 31, 2013, 2012 and 2011, approximately $139,000, $174,000 and $106,000, respectively, of the deferred credit was amortized as a reduction of operating expenses.
	We have committed to repay the Irish government for grants received if we were to cease production in Ireland prior to the expiration of the grant liability period. The grant liability period is usually between five and eight years from the last claim made on a grant. As of December 31, 2013, the total amount of grants that could be subject to refund was approximately $5 million. Our management does not currently believe we will have to repay any of these grant monies, as we have no current intention of ceasing operations in Ireland.
	Litigation. In the ordinary course of business, we are involved in various claims and litigation matters. These claims and litigation matters may include actions involving product liability, intellectual property, contractual, and employment matters. We do not believe that any such actions are likely to be, individually or in the aggregate, material to our business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity. Legal costs for these matters such as outside counsel fees and expenses are charged to expense in the period incurred.
	On April 4, 2013, we commenced litigation against Bard Access Systems, Inc. ("Bard") in the Third Judicial District Court for Salt Lake County, Utah, seeking a determination that Bard had breached a Purchasing Agreement (the "Agreement") we entered into with Specialized Health Products, Inc., which was subsequently acquired by Bard. Our complaint alleges that Bard improperly terminated the Agreement, causing us substantial damages. Bard has denied our claims, and the proceeding is currently in the discovery phase. Given the early stage of the litigation, it is not possible to estimate the potential outcome of the proceeding or the potential range of any loss; however, we intend to vigorously pursue our claims.
	Intellectual property rights, particularly patents, play a significant role in product development and help differentiate competitors in the medical device market. Competing companies may file infringement lawsuits in attempts to bolster their intellectual property portfolios or enhance their financial standing. Intellectual property litigation is time consuming, costly and unpredictable. Monetary judgments, remedies or restitution are often not determined until the conclusion of trial court proceedings, which can be modified on appeal. Accordingly, the outcomes of pending litigation are difficult to predict or quantify. On September 20, 2013, a third party filed suit for patent infringement against us in the United States District Court, District of Delaware, alleging that we infringe certain patents. The patents generally relate to aspiration catheters. The suit is in its early stages and we are still evaluating the complaint and our defenses.

Earnings_Per_Common_Share_EPS

Earnings Per Common Share (EPS)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share, Basic and Diluted [Abstract]	'
Earnings Per Common Share (EPS)	'
	EARNINGS PER COMMON SHARE (EPS)
	The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):
		Net		Shares	Per Share
		Income			Amount
	Year ended December 31, 2013:
	Basic EPS	$	16,570	42,607	$	0.39
	Effect of dilutive stock options and warrants			277
	Diluted EPS	$	16,570	42,884	$	0.39
	Year ended December 31, 2012:
	Basic EPS	$	19,710	42,176	$	0.47
	Effect of dilutive stock options and warrants			434
	Diluted EPS	$	19,710	42,610	$	0.46
	Year ended December 31, 2011:
	Basic EPS	$	23,044	39,086	$	0.59
	Effect of dilutive stock options and warrants			647
	Diluted EPS	$	23,044	39,733	$	0.58
	For the years ended December 31, 2013, 2012 and 2011, approximately 1,823,000, 1,588,000 and 909,000, respectively, of stock options were not included in the computation of diluted earnings per share because their effect would have been anti-dilutive.

Employee_Stock_Purchase_Plan_S

Employee Stock Purchase Plan Stock Options and Warrants	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Employee Stock Purchase Plan Stock Options and Warrants	'
	EMPLOYEE STOCK PURCHASE PLAN STOCK OPTIONS AND WARRANTS.
	Our stock-based compensation primarily consists of the following plans:
	2006 Long-Term Incentive Plan. In May 2006, our Board of Directors adopted and our shareholders approved, the Merit Medical Systems, Inc. 2006 Long-Term Incentive Plan (the “2006 Incentive Plan”). The 2006 Incentive Plan provides for the granting of stock options, stock appreciation rights, restricted stock, stock units (including restricted stock units) and performance awards. Options may be granted to directors, officers, outside consultants and key employees and may be granted upon such terms and such conditions as the Compensation Committee of our Board of Directors determines. Options will typically vest on an annual basis over a three to five year life (or one year if performance based) with contractual lives of seven to ten years. As of December 31, 2013, a total of approximately 1.1 million shares remained available to be issued under the 2006 Incentive Plan.
	Employee Stock Purchase Plan. We have a qualified and a non-qualified Employee Stock Purchase Plan (“ESPP”), which has an expiration date of June 30, 2016. As of December 31, 2013, the total number of shares of Common Stock that remained available to be issued under our qualified plan was approximately 229,000 shares and 60,000 shares for our non-qualified plan. ESPP participants purchase shares on a quarterly basis at a price equal to 95% of the market price of the Common Stock at the end of the applicable offering period.
	Stock-Based Compensation Expense. The stock-based compensation expense before income tax expense for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cost of goods sold	$	145			$	245			$	241
	Research and development	87				119				86
	Selling, general, and administrative	1,235				1,553				1,317
	Stock-based compensation expense before taxes	$	1,467			$	1,917			$	1,644
	We recognize stock-based compensation expense (net of a forfeiture rate) for those awards which are expected to vest on a straight-line basis over the requisite service period. We estimate the forfeiture rate based on our historical experience and expectations about future forfeitures. As of December 31, 2013, the total remaining unrecognized compensation cost related to non-vested stock options, net of expected forfeitures, was approximately $4.2 million and is expected to be recognized over a weighted average period of 3.3 years.
	In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted were estimated using the following assumptions for the periods indicated below:
		2013				2012				2011
	Risk-free interest rate	0.65%	-	1.16%		0.54%	-	0.95%		0.68%	-	1.34%
	Expected option life	4.2	-	6.0 years		4.2	-	6.0 years		4.2	-	6.0 years
	Expected dividend yield	—%				—%				—%
	Expected price volatility	34.08%	-	41.67%		42.01%	-	44.56%		42.11%	-	45.29%
	The average risk-free interest rate is determined using the U.S. Treasury rate in effect as of the date of grant, based on the expected term of the stock option. We determine the expected term of the stock options using the historical exercise behavior of employees. The expected price volatility was determined using a weighted average of daily historical volatility of our stock price over the corresponding expected option life and implied volatility based on recent trends of the daily historical volatility. For options with a vesting period, compensation expense is recognized on a straight-line basis over the service period, which corresponds to the vesting period. Compensation expense is recognized immediately for options that are fully vested on the date of grant. During the years ended December 31, 2013, 2012 and 2011, approximately 348,000, 128,000 and 844,000 stock-based compensation grants were made, respectively, for a total fair value of approximately $1.4 million, $677,000 and $4.3 million, net of estimated forfeitures, respectively.
	The table below presents information related to stock option activity for the years ended December 31, 2013, 2012 and 2011 (in thousands):
		2013				2012				2011
	Total intrinsic value of stock options exercised	$	1,649			$	3,472			$	9,433
	Cash received from stock option exercises	3,281				3,325				7,197
	Excess tax benefit from the exercise of stock options	259				877				3,122
	Changes in stock options for the year ended December 31, 2013, consisted of the following (shares and intrinsic value in thousands):
		Number			Weighted Average				Remaining Contractual		Intrinsic
		of Shares			Exercise Price				Term (in years)		Value
	2013:00:00
	Beginning balance	3,535			$	12.55
	Granted	348			12.08
	Exercised	(368	)		10.1
	Forfeited/expired	(507	)		16.43
	Outstanding at December 31	3,008			12.14				2.9		$	10,823
	Exercisable	2,075			11.73				1.9		8,312
	Ending vested and expected to vest	2,991			12.14				2.9		10,772
	The weighted average grant-date fair value of options granted during the years ended December 31, 2013, 2012 and 2011 was $4.01, $5.31 and $5.28, respectively.
	The following table summarizes information about stock options outstanding at December 31, 2013 (shares in thousands):
								Options Outstanding							Options Exercisable
	Range of Exercise							Number Outstanding			Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
	$	9.58		-	$11.05			764			1.93		$	9.96	639	$	9.97
	$	11.41		-	$12.02			859			1.25		11.68		859	11.68
	$	12.1		-	$13.75			1,094			4.9		13.53		367	13.6
	$	13.77		-	$15.12			291			3		14.03		210	14.08
	$	9.58		-	$15.12			3,008							2,075

Segment_Reporting_and_Foreign_

Segment Reporting and Foreign Operations	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting and Foreign Operations	'
	SEGMENT REPORTING AND FOREIGN OPERATIONS
	We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolization devices and the CRM/EP devices we acquired through our acquisition of Thomas Medical. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income (loss). Listed below are the sales by business segment for the years ended December 31, 2013, 2012 and 2011 (in thousands):
		% Change			2013				% Change			2012		% Change		2011
	Cardiovascular
	Stand-alone devices	10	%		$	125,445			12	%		$	114,242	15	%	$	101,959
	Custom kits and procedure trays	10	%		103,700				3	%		94,586		11	%	91,532
	Inflation devices	(4	)%		66,182				2	%		68,979		8	%	67,353
	Catheters	16	%		75,131				17	%		64,878		23	%	55,357
	Embolization devices	(1	)%		33,395				8	%		33,870		247	%	31,229
	CRM/EP	1,359	%		28,271				—	%		1,938		—	%	—
	Total	14	%		432,124				9	%		378,493		21	%	347,430
	Endoscopy
	Endoscopy devices	7	%		16,925				31	%		15,795		33	%	12,019
	Total	14	%		$	449,049			10	%		$	394,288	21	%	$	359,449
	During the years ended December 31, 2013, 2012 and 2011, we had foreign sales of approximately $165.8 million, $146.3 million and $125.9 million, respectively, or approximately 37%, 37% and 35%, respectively, of total sales, primarily in China, Japan, Germany, France, the United Kingdom and Russia. Foreign sales are attributed based on location of the customer receiving the product.
	Our long-lived assets by geographic area at December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	United States	$	178,130			$	176,644			$	134,393
	Ireland	50,274				48,182				36,008
	Other foreign countries	14,866				9,977				8,739
	Total	$	243,270			$	234,803			$	179,140
	Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2013, 2012 and 2011, are as follows (in thousands):
		2013				2012				2011
	Revenues
	Cardiovascular	$	432,124			$	378,493			$	347,430
	Endoscopy	16,925				15,795				12,019
	Total revenues	449,049				394,288				359,449
	Operating expenses
	Cardiovascular	157,479				142,089				122,600
	Endoscopy	9,044				10,262				9,678
	Total operating expenses	166,523				152,351				132,278
	Operating income (loss)
	Cardiovascular	26,597				30,411				38,010
	Endoscopy	1,247				(770		)		(4,820		)
	Total operating income	27,844				29,641				33,190
	Total other expense - net	(8,005		)		(2,023		)		(315		)
	Income tax expense	3,269				7,908				9,831
	Net income	$	16,570			$	19,710			$	23,044
	Total assets by business segment at December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cardiovascular	$	716,659			$	692,689			$	434,747
	Endoscopy	11,624				12,620				12,270
	Total	$	728,283			$	705,309			$	447,017
	Total depreciation and amortization by business segment for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cardiovascular	$	31,594			$	21,441			$	18,219
	Endoscopy	948				1,093				975
	Total	$	32,542			$	22,534			$	19,194
	Total capital expenditures by business segment for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cardiovascular	$	59,421			$	64,059			$	58,775
	Endoscopy	84				584				420
	Total	$	59,505			$	64,643			$	59,195

Royalty_Agreements

Royalty Agreements	12 Months Ended
	Dec. 31, 2013
Royalty Agreements [Abstract]	'
Royalty Agreements	'
	ROYALTY AGREEMENTS
	During 2007, in connection with the purchase of the ProGuide™ chronic dialysis catheter from Datascope, we entered into a running royalty agreement as partial consideration of the assignment of acquired intellectual property to us. Under this agreement, we agreed to pay Datascope a royalty of 5% of net sales, with annual minimum royalty payments of $50,000 for calendar years 2009 through 2013. During each of the years ended December 31, 2013, 2012 and 2011, we paid or accrued a royalty of $50,000 under this agreement. Our fiscal royalty payments under this agreement will cease after February 2014.
	During 2010, in connection with our acquisition of BioSphere, we entered into a running royalty agreement as part of a partnership between BioSphere and L’Assistance Publique-Hôpitaux de Paris, referred to as “AP-HP,” pursuant to which AP-HP has granted us the exclusive license to use two United States patents and their foreign counterparts that we jointly own with AP-HP relating to microspheres. We are required to pay to AP-HP a royalty on the commercial sale of any products that incorporate technology covered by the subject patents. We may sublicense these exclusive rights under the agreement only with the prior written consent of AP-HP, which consent cannot be unreasonably withheld. Under the terms of the royalty agreement, our exclusive license extends for both (i) the term of jointly owned U.S. and foreign counterpart patents and (ii) as long as the products and specialties implementing the patents are marketed. BioSphere filed patent applications which, if issued, will expire in approximately January 2031. The royalty rate in the agreement is 5.0% of net sales until the patents expire, and 2.5% of net sales thereafter as long as the product is sold. We paid or accrued approximately $1.3 million, $1.4 million and $1.3 million in royalty payments to AP-HP for the years ended December 31, 2013, 2012 and 2011, respectively, after the BioSphere acquisition.
	See Note 2 for a discussion of additional future royalty commitments related to acquisitions.

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'
Employee Benefit Plans	'
	EMPLOYEE BENEFIT PLANS
	We have a contributory 401(k) savings and profit sharing plan (the “Plan”) covering all U.S. full-time employees who are at least 18 years of age. The Plan has a 90-day minimum service requirement. We may contribute, at our discretion, matching contributions based on the employees’ compensation. Contributions we made to the Plan for the years ended December 31, 2013, 2012 and 2011, totaled approximately $429,000, $1.5 million and $1.2 million, respectively. We have defined contribution plans covering some of our foreign employees. We contribute between three percent and 31% of the employee’s compensation for certain foreign non-management employees, and between ten percent and 31% of the employee’s compensation for certain foreign management employees. Contributions made to these plans for the years ended December 31, 2013, 2012 and 2011, totaled approximately $748,000, $724,000 and $469,000, respectively.

Quarterly_Results_of_Operation

Quarterly Results of Operations (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Results of Operations (Unaudited)	'
	QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)
	Quarterly data for the years ended December 31, 2013 and 2012 consisted of the following (in thousands, except per share amounts):
		Quarter Ended
		March 31			June 30		September 30		December 31
	2013
	Net sales	$	103,948		$	109,875	$	115,210	$	120,016
	Gross profit	42,993			46,985		51,030		53,359
	Income from operations	1,757			6,780		8,391		10,916
	Income tax expense (benefit)	(459		)	1,253		833		1,642
	Net income	671			3,752		5,607		6,540
	Basic earnings per common share	0.02			0.09		0.13		0.15
	Diluted earnings per common share	0.02			0.09		0.13		0.15
	2012
	Net sales	$	95,618		$	100,532	$	95,907	$	102,231
	Gross profit	44,170			47,024		45,335		45,463
	Income from operations	8,007			8,222		9,082		4,330
	Income tax expense	2,169			2,719		1,811		1,209
	Net income	5,748			6,095		7,226		641
	Basic earnings per common share	0.14			0.14		0.17		0.02
	Diluted earnings per common share	0.14			0.14		0.17		0.01
	Basic and diluted earnings per share are computed independently for each of the quarters presented. Therefore, the sum of the quarterly amounts may not equal the total computed for the year.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	Our financial assets and (liabilities) carried at fair value measured on a recurring basis as of December 31, 2013 and 2012, consisted of the following (in thousands):
							Fair Value Measurements Using
			Total Fair				Quoted prices in			Significant other			Significant
			Value at				active markets			observable inputs			Unobservable inputs
	Description		31-Dec-13				(Level 1)			(Level 2)			(Level 3)
	Interest rate swap (1)		$	1,203			$	—		$	1,203		$	—
							Fair Value Measurements Using
			Total Fair				Quoted prices in			Significant other			Significant
			Value at				active markets			observable inputs			Unobservable inputs
	Description		31-Dec-12				(Level 1)			(Level 2)			(Level 3)
	Interest rate swap (1)		$	(1,788	)		$	—		$	(1,788	)	$	—
	(1)    The fair value of the interest rate swap is determined based on forward yield curves.
	Certain of our business combinations involve the potential for the payment of future contingent consideration, generally based on a percentage of future product sales or upon attaining specified future revenue milestones. See Note 2 for further information regarding these acquisitions. The contingent consideration liability is re-measured at the estimated fair value at each reporting period with the change in fair value recognized within selling, general, and administrative expenses in the accompanying consolidated statements of income. We measure the initial liability and re-measure the liability on a recurring basis using Level 3 inputs as defined under authoritative guidance for fair value measurements. Changes in the fair value of our contingent consideration liability during the years ended December 31, 2013 and 2012, consisted of the following (in thousands):
		2013				2012
	Beginning balance	$	6,697			$	1,290
	Contingent consideration liability recorded as the result of acquisitions (see Note 2)	—				4,704
	Initial purchase price adjustments finalized over the period (see Note 2)	—				280
	Fair value adjustments recorded to (income) expense during the period	(4,094		)		480
	Contingent payments made	(77		)		(57		)
	Ending balance	$	2,526			$	6,697
	The recurring Level 3 measurement of our contingent consideration liability includes the following significant unobservable inputs at December 31, 2013 and 2012 (amount in thousands):
	Contingent consideration liability		Fair value at December 31, 2013				Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	2,282			Discounted cash flow		Discount rate	11% - 15%
									Probability of milestone payment	90%
									Projected year of payments	2014-2028
	Other payments		$	244			Discounted cash flow		Discount rate	5.40%
									Probability of milestone payment	100%
									Projected year of payments	2014-2016
	Contingent consideration liability		Fair value at December 31, 2012				Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	6,370			Discounted cash flow		Discount rate	10% - 14.5%
									Probability of milestone payment	90%
									Projected year of payments	2013-2028
	Other payments		$	327			Discounted cash flow		Discount rate	4.50%
									Probability of milestone payment	100%
									Projected year of payments	2013-2015
	The contingent consideration liability is re-measured to fair value each reporting period using projected revenues, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases (decreases) in discount rates and the time to payment may result in lower (higher) fair value measurements. A decrease in the probability of any milestone payment may result in lower fair value measurements. An increase (decrease) in either the discount rate or the time to payment, in isolation, may result in a significantly lower (higher) fair value measurement.
	Our determination of the fair value of the contingent consideration liability could change in future periods based upon our ongoing evaluation of these significant unobservable inputs. We intend to record any such change in fair value to selling, general, and administrative expenses in our consolidated statements of income. As of December 31, 2013, approximately $2.3 million was included in other long-term obligations and $274,000 was included in accrued expenses in our consolidated balance sheet. As of December 31, 2012, approximately $5.9 million was included in other long-term obligations and $723,000 was included in accrued expenses in our consolidated balance sheet. The cash paid to settle the contingent consideration liability recognized at fair value as of the acquisition date (including measurement-period adjustments) has been reflected as a cash outflow from financing activities in the accompanying consolidated statements of cash flows.
	During the years ended December 31, 2013, 2012 and 2011, we had losses of approximately $8.2 million, $55,000, and $103,000, respectively, related to the measurement of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition. Of the total loss in 2013, approximately $8.1 million  related to the impairment of our intangible assets related to our Ostial acquisition (see Note 4) during the quarter ended September 30, 2013. The non-recurring fair values of the Ostial intangible assets as of September 30, 2013 were approximately $1.5 million for developed technology and $160,000 for other intangible assets. The fair value of these non-financial assets was measured using Level 3 inputs.
	During the quarter ended December 31, 2012, we recognized an impairment charge of approximately $2.4 million, which is included in other expense in the accompanying consolidated statement of income, related to an investment in a privately-held company accounted for at cost. As of December 31, 2012, there was no remaining cost included in our consolidated balance sheets related to this investment, which we deemed to be an appropriate valuation methodology due to the financial position of the investee.
	The carrying amount of cash and cash equivalents, receivables, and trade payables approximates fair value because of the immediate, short-term maturity of these financial instruments. The carrying amount of long-term debt approximates fair value, as determined by borrowing rates estimated to be available to us for debt with similar terms and conditions. The fair value of assets and liabilities whose carrying value approximates fair value is determined using Level 2 inputs, with the exception of cash and cash equivalents (Level 1).

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	STOCKHOLDERS' EQUITY
	Issuance of Common Stock. On June 22, 2011, we completed an equity public offering of 5,520,000 shares of Common Stock and received proceeds of approximately $87.7 million, which is net of approximately $4.6 million in underwriting discounts and commissions and approximately $127,000 in other direct costs incurred and paid by us in connection with this equity offering.
	Stock Split. On April 21, 2011, our Board of Directors authorized a 5-for-4 forward stock split of our Common Stock, which was effected in the form of a stock dividend of one share of Common Stock for every four shares of Common Stock outstanding on the record date. On May 5, 2011, we completed the forward stock split through a stock dividend to shareholders of record as of May 2, 2011. Our Board of Directors also made corresponding adjustments to the number of shares subject to, and the exercise price of, outstanding options and other rights to acquire shares of our Common Stock. All earnings per common share and common share data set forth in the foregoing consolidated financial statements (and notes thereto) have been adjusted to reflect the split.

Schedule_II_Valuation_and_qual

Schedule II - Valuation and qualifying accounts	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]	'
Schedule II - Valuation and qualifying accounts	'
	(2) Financial Statement Schedule.
	—                                   Schedule II - Valuation and qualifying accounts
	Years Ended December 31, 2013, 2012 and 2011
	(In thousands)
	Description	Balance at			Additions Charged to			Deduction (b)		Balance at
		Beginning of Year			Costs and Expenses (a)					End of Year
	ALLOWANCE FOR UNCOLLECTIBLE ACCOUNTS:
	2011	$	(593	)	$	(12	)	$	141	$	(464	)
	2012	(464		)	(545		)	117		(892		)
	2013	(892		)	(376		)	428		(840		)
	(a) We record a bad debt provision based upon historical experience and a review of individual customer balances.
	(b) When an individual customer balance becomes impaired and is deemed uncollectible a deduction is made against the allowance for uncollectible accounts.
	Years Ended December 31, 2013, 2012 and 2011
	(In thousands)
	Description	Balance at			Additions Charged to			Deduction		Balance at
		Beginning of Year			Costs and Expenses (c)					End of Year
	TAX VALUATION ALLOWANCE:
	2011	$	—		$	(361	)	$	—	$	(361	)
	2012	(361		)	(864		)	—		(1,225		)
	2013	(1,225		)	(138		)	—		(1,363		)
	(c) We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Use of Estimates, Policy	'
	Use of Estimates in Preparing Financial Statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Consolidation, Policy	'
	Principles of Consolidation. The consolidated financial statements include our wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated.
Cash and Cash Equivalents, Policy	'
	Cash and Cash Equivalents. For purposes of the statements of cash flows, we consider interest bearing deposits with an original maturity date of three months or less to be cash equivalents.
Receivables, Policy	'
	Receivables. The allowance for uncollectible accounts receivable is based on our historical bad debt experience and on management’s evaluation of our ability to collect individual outstanding balances.
Inventory, Policy	'
	Inventories. We value our inventories at the lower of cost, determined on a first-in, first-out method, or market value.  Market value for raw materials is based on replacement costs. Inventory costs include material, labor and manufacturing overhead.  We review inventories on hand at least quarterly and record provisions for estimated excess, slow moving and obsolete inventory, as well as inventory with a carrying value in excess of net realizable value. The regular and systematic inventory valuation reviews include a current assessment of future product demand, historical experience and product expiration.
Goodwill and Intangible Assets, Policy	'
	Goodwill and Intangible Assets. We test goodwill balances as of July 1 for impairment on an annual basis during the third quarter, or whenever impairment indicators arise. We utilize several reporting units in evaluating goodwill for impairment. We assess the estimated fair value of reporting units using a combination of a market-based approach with a guideline public company method and a discounted cash flow methodology. If the carrying amount of a reporting unit exceeds the fair value of the reporting unit, an impairment charge is recognized in an amount equal to the excess of the carrying amount of the reporting unit goodwill over the implied fair value of that goodwill.
	We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:
	Customer lists	2	-	15 years
	Developed technology	5	-	15 years
	Distribution agreements	4	-	12 years
	License agreements and trademarks	5	-	15 years
	Covenant not to compete	3	-	10 years
	Patents	17 years
	Royalty agreements	5 years
Impairment or Disposal of Long-Lived Assets, Policy	'
	Long-Lived Assets. We periodically review the carrying amount of our long-lived assets for impairment. An asset is considered impaired when estimated future cash flows are less than the carrying amount of the asset. In the event the carrying amount of such asset is not considered recoverable, the asset is adjusted to its fair value. Fair value is generally determined based on discounted future cash flow. There were no impairments of long-lived assets during the years ended December 31, 2013, 2012 and 2011.
Property, Plant and Equipment, Policy	'
	Property and Equipment. Property and equipment is stated at the historical cost of construction or purchase. Construction costs include interest costs capitalized during construction. Maintenance and repairs of property and equipment are charged to operations as incurred. Leasehold improvements are amortized over the lesser of the base term of the lease or estimated life of the leasehold improvements. Construction-in-process consists of new buildings and various production equipment being constructed internally and externally. Assets in construction-in-process will commence depreciating once the asset has been placed in service. Depreciation is computed using the straight-line method over estimated useful lives as follows:
	Buildings	40 years
	Manufacturing equipment	4	-	20 years
	Furniture and fixtures	3	-	20 years
	Land improvements	10	-	20 years
	Leasehold improvements	4	-	25 years
Deferred compensation policy text block	'
	Deferred Compensation. We have a deferred compensation plan that permits certain management employees to defer a portion of their salary until the future. We established a Rabbi trust to finance obligations under the plan with corporate-owned variable life insurance contracts.
Investment, Policy	'
	Marketable Securities. Marketable securities consisted entirely of available-for-sale equity securities. As of December 31, 2011, these equity securities had a cost basis of approximately $2.5 million, fair value of approximately $2.8 million, and gross unrealized gains that were included in accumulated other comprehensive income of approximately $295,000. There were no marketable securities held as of December 31, 2013 or December 31, 2012.
Other assets policy text block	'
	Other Assets. Other assets consist of our deferred compensation plan cash surrender value discussed above, unamortized debt issuance costs, two investments in privately-held companies accounted for at cost, a long-term income tax refund receivable, and deposits related to various leases.
Deferred credits	'
	Deferred Credits. Deferred credits consist of grant money received from the Irish government. Grant money is received for a percentage of expenditures on eligible property and equipment, specific research and development projects and costs of hiring and training employees. Amounts related to the acquisition of property and equipment are amortized as a reduction of depreciation expense over the lives of the corresponding property and equipment.
Revenue Recognition, Policy	'
	Revenue Recognition. We sell our single-use disposable medical products through a direct sales force in the U.S., through OEM relationships, custom procedure tray manufacturers and a combination of direct sales force and independent distributors in international markets. Revenues from these customers are recognized when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the price is fixed or determinable and (iv) the ability to collect is reasonably assured. These criteria are generally satisfied at the time of shipment when risk of loss and title passes to the customer. We have certain written agreements with group purchasing organizations to sell our products to participating hospitals. These agreements have destination shipping terms which require us to defer the recognition of a sale until the product has arrived at the participating hospitals. We reserve for sales returns, including returns related to defective products (i.e. warranty liability), as a reduction in net sales, based on our historical experience. We also offer sales rebates and discounts to purchasing groups. These reserves are recorded as a reduction in net sales and are not considered material to our consolidated statements of income for the years ended December 31, 2013, 2012 and 2011. In addition, we invoice our customers for taxes assessed by governmental authorities such as sales tax and value added taxes. We present these taxes on a net basis.
Shipping and Handling Cost, Policy	'
	Shipping and Handling. We bill our customers for shipping and handling charges, which are included in net sales for the applicable period, and the corresponding shipping and handling expense is reported in cost of sales.
Cost of Sales, Policy	'
	Cost of Sales. We include product costs (i.e. material, direct labor and overhead costs), shipping and handling expense, product royalty expense, developed technology amortization expense, production-related depreciation expense and product license agreement expense in cost of sales.
Research and Development Expense, Policy	'
	Research and Development. Research and development costs are expensed as incurred.
Income Tax, Policy	'
	Income Taxes. We utilize an asset and liability approach for financial accounting and reporting for income taxes. Deferred income taxes are provided for temporary differences in the basis of assets and liabilities as reported for financial statement and income tax purposes. Deferred income taxes reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings, if any. We make estimates and judgments in determining the need for a provision for income taxes, including the estimation of our taxable income for each full fiscal year.
Earnings Per Share, Policy	'
	Earnings per Common Share. Net income per common share is computed by both the basic method, which uses the weighted average number of our common shares outstanding and the diluted method, which includes the dilutive common shares from stock options and warrants, as calculated using the treasury stock method.
Fair Value of Financial Instruments, Policy	'
	Fair Value Measurements. The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories:
	Level 1: Quoted market prices in active markets for identical assets or liabilities.
	Level 2: Observable market-based inputs or inputs that are corroborated by market data.
	Level 3: Unobservable inputs that are not corroborated by market data.
Share-based Compensation, Option and Incentive Plans Policy	'
	Stock-Based Compensation. We recognize the fair value compensation cost relating to share-based payment transactions in accordance with Accounting Standards Codification (“ASC”) 718, Compensation — Stock Compensation. Under the provisions of ASC 718, share-based compensation cost is measured at the grant date, based on the fair value of the award and is recognized over the employee’s requisite service period, which is generally the vesting period. The fair value of our stock options is estimated using a Black-Scholes option valuation model.
Concentration of Credit Risk	'
	Concentration of Credit Risk. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. We provide credit, in the normal course of business, primarily to hospitals and independent third-party custom procedure tray manufacturers and distributors. We perform ongoing credit evaluations of our customers and maintain allowances for potential credit losses.
Foreign Currency Transactions and Translations Policy	'
	Foreign Currency. The financial statements of our foreign subsidiaries are measured using local currencies as the functional currency, with the exception of Ireland which uses the U.S. Dollar as its functional currency. Assets and liabilities are translated into U.S. Dollars at year-end rates of exchange and results of operations are translated at average rates for the year. Gains and losses resulting from these translations are included in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Foreign currency transactions denominated in a currency other than the entity’s functional currency are included in determining net income for the period. Such foreign currency transaction gains and losses have not been significant for purposes of our financial reporting.
Derivatives, Policy	'
	Derivatives. We use forward contracts to mitigate our exposure to volatility in foreign exchange rates, and we used an interest rate swap to hedge changes in the benchmark interest rate related to our Credit Agreement described in Note 7 below. All derivatives are recognized in the consolidated balance sheets at fair value. Classification of each hedging instrument is based upon whether the maturity of the instrument is less than or greater than 12 months. We do not purchase or hold derivative financial instruments for speculative or trading purposes. See Note 8.
Accumulated Other Comprehensive Income (Loss)	'
	Accumulated Other Comprehensive Income (Loss). As of December 31, 2013, accumulated other comprehensive income (loss) included approximately $735,000 (net of tax of $(468,000)) related to an interest rate swap and $208,000 (net of tax of $12,000) related to foreign currency translation. As of December 31, 2012, accumulated other comprehensive income (loss) included approximately $(1.1) million (net of tax of $696,000) related to an interest rate swap and ($89,000) (net of tax of $7,000) related to foreign currency translation.
New Accounting Pronouncements and Changes in Accounting Principles	'
	Recently Issued Financial Accounting Standards. In July 2013, the Financial Accounting Standards Board ("FASB"), issued authoritative guidance which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. We adopted this guidance early, as permitted, for the fiscal year ended December 31, 2013. The adoption of this guidance did not have a material effect on our consolidated financial statements.
	In March 2013, the FASB issued amendments to address the accounting for the cumulative translation adjustment when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a non-profit activity or a business within a foreign entity. The amendments are effective prospectively for fiscal years (and interim reporting periods within those years) beginning after December 15, 2013 (early adoption is permitted). The adoption of this guidance is not expected to have a material effect on our consolidated financial position or results of operations.
	In February 2013, the FASB issued amendments to disclosure requirements for presentation of comprehensive income. The standard requires presentation (either in a single note or parenthetically on the face of the financial statements) of the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source and the income statement line items affected by the reclassification. If a component is not required to be reclassified to net income in its entirety, a cross reference to the related footnote for additional information is required. The amendments are effective prospectively for reporting periods beginning after December 15, 2012. The adoption of this guidance did not have a material effect on our consolidated financial statements.
	In July 2012, the FASB issued authoritative guidance related to testing indefinite-lived intangible assets for impairment. This guidance simplifies how entities test indefinite-lived intangible assets for impairment and permits an entity to first assess qualitative factors to determine whether it is more likely than not that the indefinite-lived intangible asset is impaired. This guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, with early adoption permitted. The adoption of this guidance did not have a material effect on our consolidated financial statements.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Intangible Assets	'
	Intangible assets are amortized on a straight-line basis, except for customer lists, which are generally amortized on an accelerated basis, over the following useful lives:
	Customer lists	2	-	15 years
	Developed technology	5	-	15 years
	Distribution agreements	4	-	12 years
	License agreements and trademarks	5	-	15 years
	Covenant not to compete	3	-	10 years
	Patents	17 years
	Royalty agreements	5 years
Property and Equipment	'
	Depreciation is computed using the straight-line method over estimated useful lives as follows:
	Buildings	40 years
	Manufacturing equipment	4	-	20 years
	Furniture and fixtures	3	-	20 years
	Land improvements	10	-	20 years
	Leasehold improvements	4	-	25 years

Acquisitions_Tables

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Thomas Medical Products, Inc	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price was allocated as follows (in thousands):
	Assets Acquired
	Trade receivables	$	6,507
	Inventories	5,459
	Prepaid expenses	340
	Property and equipment	2,685
	Intangibles
	Developed technology	43,000
	Non-compete agreements	500
	Customer lists	5,000
	Trademarks	1,400
	Goodwill	102,407
	Total assets acquired	167,298
	Liabilities Assumed
	Trade payables	588
	Accrued expenses	1,094
	Total liabilities assumed	1,682
	Net assets acquired, net of cash acquired of $1,829	$	165,616
Business Acquisition, Pro Forma Information	'
	The following table summarizes our unaudited consolidated results of operations for the years ended December 31, 2013, 2012 and 2011, as well as unaudited pro forma consolidated results of operations as though the Thomas Medical, MediGroup, and Ostial acquisitions had occurred on January 1, 2011 and the Datascope acquisition had occurred on January 1, 2012 (in thousands, except per common share amounts):
		2013				2012				2011
		As Reported		Pro Forma		As Reported		Pro Forma		As Reported		Pro Forma
	Net sales	$	449,049	$	454,333	$	394,288	$	438,981	$	359,449	$	396,767
	Net income	16,570		17,112		19,710		25,075		23,044		22,033
	Earnings per common share:
	Basic	$	0.39	$	0.4	$	0.47	$	0.59	$	0.59	$	0.56
	Diluted	$	0.39	$	0.4	$	0.46	$	0.59	$	0.58	$	0.55
MediGroup	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	263
	Property and equipment	79
	Intangibles
	Developed technology	2,000
	Non-compete agreements	210
	Customer lists	110
	Trademarks	80
	Goodwill	1,697
	Total assets acquired	$	4,439
Ostial Solutions, LLC	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	It is not practical to separately report the earnings related to the Ostial acquisition, as we cannot split out sales costs related to Ostial products, principally because our sales representatives are selling multiple products (including Ostial products) in the cardiovascular business segment. The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Intangibles
	Developed technology	$	10,500
	Customer lists	600
	Trademark	110
	Non-compete agreements	10
	Goodwill	9,580
	Total assets acquired	$	20,800
Ash	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price, which includes the contingent consideration liability described above, was allocated as follows (in thousands):
	Assets Acquired
	Property and equipment	$	73
	Intangibles
	Developed technology	3,200
	Customer lists	300
	Goodwill	2,697
	Total assets acquired	$	6,270
Datascope	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price was preliminarily allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	478
	Intangibles
	Developed technology	18,200
	Customer lists	390
	Trademarks	320
	Goodwill	8,112
	Total assets acquired	$	27,500
Radial Assist	'
Business Acquisition [Line Items]	'
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	'
	The total purchase price was preliminarily allocated as follows (in thousands):
	Assets Acquired
	Inventories	$	16
	Intangibles
	Developed technology	1,520
	Customer lists	20
	Trademarks	40
	Goodwill	904
	Total assets acquired	$	2,500

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventories at December 31, 2013 and 2012, consisted of the following (in thousands):
		2013		2012
	Finished goods	$	43,364	$	48,233
	Work-in-process	6,222		6,051
	Raw materials	32,792		30,315
	Total	$	82,378	$	84,599

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in carrying amount of goodwill	'
	The changes in the carrying amount of goodwill for the years ended December 31, 2013 and 2012, are as follows (in thousands):
		2013		2012
	Goodwill balance at January 1	$	175,108	$	61,144
	Adjustment related to previous acquisitions	381		280
	Additions as the result of acquisitions	9,016		113,684
	Goodwill balance at December 31	$	184,505	$	175,108
Other intangible assets	'
	Other intangible assets at December 31, 2013 and 2012, consisted of the following (in thousands):
		2013
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Patents	$	9,302	$	(2,374	)	$	6,928
	Distribution agreements	5,176		(1,780		)	3,396
	License agreements	3,783		(1,249		)	2,534
	Trademarks	7,622		(1,844		)	5,778
	Covenants not to compete	1,029		(399		)	630
	Customer lists	20,626		(10,957		)	9,669
	Royalty agreements	267		(267		)	—
	Total	$	47,805	$	(18,870	)	$	28,935
		2012
		Gross					Net
		Carrying		Accumulated			Carrying
		Amount		Amortization			Amount
	Patents	$	7,843	$	(2,045	)	$	5,798
	Distribution agreements	5,176		(1,301		)	3,875
	License agreements	2,733		(861		)	1,872
	Trademarks	7,311		(1,362		)	5,949
	Covenants not to compete	1,035		(160		)	875
	Customer lists	20,468		(8,038		)	12,430
	Royalty agreements	267		(267		)	—
	Total	$	44,833	$	(14,034	)	$	30,799
Estimated amortization expense	'
	Estimated amortization expense for the intangible assets for the next five years consists of the following as of December 31, 2013 (in thousands):
	Year Ending December 31
	2014	$	15,189
	2015	14,751
	2016	14,094
	2017	13,678
	2018	13,158

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax, Domestic and Foreign	'
	For the years ended December 31, 2013, 2012 and 2011, income before income taxes is broken out between U.S. and foreign-sourced operations and consisted of the following (in thousands):
		2013			2012			2011
	Domestic	$	5,435		$	15,958		$	21,123
	Foreign	14,404			11,660			11,752
	Total	$	19,839		$	27,618		$	32,875
Schedule of Components of Income Tax Expense (Benefit)	'
	The components of the provision for income taxes for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013			2012			2011
	Current expense (benefit):
	Federal	$	(747	)	$	5,350		$	5,662
	State	333			1,014			1,001
	Foreign	2,324			995			1,491
	Total current expense	1,910			7,359			8,154
	Deferred expense (benefit):
	Federal	1,089			871			1,121
	State	278			(343		)	74
	Foreign	(8		)	21			482
	Total deferred expense	1,359			549			1,677
	Total	$	3,269		$	7,908		$	9,831
Schedule of Effective Income Tax Rate Reconciliation	'
	The difference between the income tax expense reported and amounts computed by applying the statutory federal rate of 35.0% to pretax income for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013			2012			2011
	Computed federal income tax expense at statutory rate of 35%	$	6,943		$	9,667		$	11,506
	State income taxes	397			436			699
	Tax credits	(1,385		)	(779		)	(778		)
	Production activity deduction	—			(388		)	(425		)
	Foreign tax rate differential	(2,374		)	(1,419		)	(1,297		)
	Uncertain tax positions	(520		)	(42		)	281
	Deferred compensation insurance assets	(358		)	(155		)	88
	Other — including the effect of graduated rates	566			588			(243		)
	Total income tax expense	$	3,269		$	7,908		$	9,831
Schedule of Deferred Tax Assets and Liabilities	'
	Deferred income tax assets and liabilities at December 31, 2013 and 2012, consisted of the following temporary differences and carry-forward items (in thousands):
		2013			2012
	Deferred income tax assets:
	Allowance for uncollectible accounts receivable	$	342		$	348
	Accrued compensation expense	5,001			3,954
	Inventory differences	2,317			1,949
	Net operating loss carry-forwards	18,060			19,622
	Deferred revenue	280			237
	Stock-based compensation expense	2,704			2,465
	Uncertain tax positions	559			709
	Federal research and development credit carry-forward	569			—
	Other	3,197			3,762
	Total deferred income tax assets	33,029			33,046
	Deferred income tax liabilities:
	Prepaid expenses	(751		)	(757		)
	Property and equipment	(21,893		)	(19,001		)
	Intangible assets	(3,837		)	(4,107		)
	Other	(1,295		)	(1,116		)
	Total deferred income tax liabilities	(27,776		)	(24,981		)
	Valuation allowance	(1,363		)	(1,225		)
	Net deferred income tax assets	$	3,890		$	6,840
	Reported as:
	Deferred income tax assets - Current	$	5,638		$	4,976
	Deferred income tax assets - Long-term	800			4,237
	Deferred income tax liabilities - Current	—			—
	Deferred income tax liabilities - Long-term	(2,548		)	(2,373		)
	Net deferred income tax assets	$	3,890		$	6,840
Summary of Income Tax Contingencies	'
	A reconciliation of the beginning and ending amount of liabilities associated with uncertain tax benefits for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
	Tabular Roll-forward	2013			2012			2011
	Unrecognized tax benefits, opening balance	$	2,776		$	3,113		$	2,952
	Gross increases in tax positions taken in a prior year	107			83			347
	Gross increases in tax positions taken in the current year	236			260			865
	Settlements with taxing authorities	—			—			(507		)
	Lapse of applicable statute of limitations	(990		)	(680		)	(544		)
	Unrecognized tax benefits, ending balance	$	2,129		$	2,776		$	3,113

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities	'
	Accrued expenses at December 31, 2013 and 2012, consisted of the following (in thousands):
		2013		2012
	Payroll taxes	$	1,816	$	1,893
	Payroll	3,474		3,141
	Bonuses	5,273		5,778
	Commissions	984		894
	Vacation	6,280		5,066
	Royalties	1,221		1,368
	Value-added tax	1,469		1,158
	Other accrued expenses	7,185		7,971
	Total	$	27,702	$	27,269

Revolving_Credit_Facility_and_1

Revolving Credit Facility and Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-term Debt Instruments	'
	In summary, principal balances under our long-term debt as of December 31, 2013 and 2012, consisted of the following (in thousands):
		2013			2012
	Term loan	$	92,500		$	100,000
	Revolving credit loans	156,354			137,566
	Total long-term debt	248,854			237,566
	Less current portion	10,000			10,000
	Long-term portion	$	238,854		$	227,566
Schedule of Maturities of Long-term Debt	'
	Future minimum principal payments on our long-term debt as of December 31, 2013, are as follows (in thousands):
	Years Ending		Future Minimum
	December 31		Principal Payments
	2014		$	10,000
	2015		10,000
	2016		10,000
	2017		218,854
	Total future minimum principal payments		$	248,854

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	The future minimum lease payments for operating leases as of December 31, 2013, consisted of the following (in thousands):
	Years Ending	Operating
	December 31	Leases
	2014	$	6,569
	2015	5,956
	2016	4,974
	2017	4,122
	2018	4,073
	Thereafter	36,067
	Total minimum lease payments	$	61,761

Earnings_Per_Common_Share_EPS_

Earnings Per Common Share (EPS) (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share, Basic and Diluted [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the following periods consisted of the following (in thousands, except per share amounts):
		Net		Shares	Per Share
		Income			Amount
	Year ended December 31, 2013:
	Basic EPS	$	16,570	42,607	$	0.39
	Effect of dilutive stock options and warrants			277
	Diluted EPS	$	16,570	42,884	$	0.39
	Year ended December 31, 2012:
	Basic EPS	$	19,710	42,176	$	0.47
	Effect of dilutive stock options and warrants			434
	Diluted EPS	$	19,710	42,610	$	0.46
	Year ended December 31, 2011:
	Basic EPS	$	23,044	39,086	$	0.59
	Effect of dilutive stock options and warrants			647
	Diluted EPS	$	23,044	39,733	$	0.58

Employee_Stock_Purchase_Plan_S1

Employee Stock Purchase Plan Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	The stock-based compensation expense before income tax expense for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cost of goods sold	$	145			$	245			$	241
	Research and development	87				119				86
	Selling, general, and administrative	1,235				1,553				1,317
	Stock-based compensation expense before taxes	$	1,467			$	1,917			$	1,644
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	'
	In applying the Black-Scholes methodology to the option grants, the fair value of our stock-based awards granted were estimated using the following assumptions for the periods indicated below:
		2013				2012				2011
	Risk-free interest rate	0.65%	-	1.16%		0.54%	-	0.95%		0.68%	-	1.34%
	Expected option life	4.2	-	6.0 years		4.2	-	6.0 years		4.2	-	6.0 years
	Expected dividend yield	—%				—%				—%
	Expected price volatility	34.08%	-	41.67%		42.01%	-	44.56%		42.11%	-	45.29%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable	'
	The table below presents information related to stock option activity for the years ended December 31, 2013, 2012 and 2011 (in thousands):
		2013				2012				2011
	Total intrinsic value of stock options exercised	$	1,649			$	3,472			$	9,433
	Cash received from stock option exercises	3,281				3,325				7,197
	Excess tax benefit from the exercise of stock options	259				877				3,122
Schedule of Share-based Compensation, Stock Options, Activity	'
	Changes in stock options for the year ended December 31, 2013, consisted of the following (shares and intrinsic value in thousands):
		Number			Weighted Average				Remaining Contractual		Intrinsic
		of Shares			Exercise Price				Term (in years)		Value
	2013:00:00
	Beginning balance	3,535			$	12.55
	Granted	348			12.08
	Exercised	(368	)		10.1
	Forfeited/expired	(507	)		16.43
	Outstanding at December 31	3,008			12.14				2.9		$	10,823
	Exercisable	2,075			11.73				1.9		8,312
	Ending vested and expected to vest	2,991			12.14				2.9		10,772
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range	'
	The following table summarizes information about stock options outstanding at December 31, 2013 (shares in thousands):
								Options Outstanding							Options Exercisable
	Range of Exercise							Number Outstanding			Weighted Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price
	$	9.58		-	$11.05			764			1.93		$	9.96	639	$	9.97
	$	11.41		-	$12.02			859			1.25		11.68		859	11.68
	$	12.1		-	$13.75			1,094			4.9		13.53		367	13.6
	$	13.77		-	$15.12			291			3		14.03		210	14.08
	$	9.58		-	$15.12			3,008							2,075

Segment_Reporting_and_Foreign_1

Segment Reporting and Foreign Operations (Tables)	12 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Revenue from External Customers by Products and Services	'
	Listed below are the sales by business segment for the years ended December 31, 2013, 2012 and 2011 (in thousands):
		% Change			2013				% Change			2012		% Change		2011
	Cardiovascular
	Stand-alone devices	10	%		$	125,445			12	%		$	114,242	15	%	$	101,959
	Custom kits and procedure trays	10	%		103,700				3	%		94,586		11	%	91,532
	Inflation devices	(4	)%		66,182				2	%		68,979		8	%	67,353
	Catheters	16	%		75,131				17	%		64,878		23	%	55,357
	Embolization devices	(1	)%		33,395				8	%		33,870		247	%	31,229
	CRM/EP	1,359	%		28,271				—	%		1,938		—	%	—
	Total	14	%		432,124				9	%		378,493		21	%	347,430
	Endoscopy
	Endoscopy devices	7	%		16,925				31	%		15,795		33	%	12,019
	Total	14	%		$	449,049			10	%		$	394,288	21	%	$	359,449
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	'
	Our long-lived assets by geographic area at December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	United States	$	178,130			$	176,644			$	134,393
	Ireland	50,274				48,182				36,008
	Other foreign countries	14,866				9,977				8,739
	Total	$	243,270			$	234,803			$	179,140
Schedule of Segment Reporting Information, by Segment	'
	Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the years ended December 31, 2013, 2012 and 2011, are as follows (in thousands):
		2013				2012				2011
	Revenues
	Cardiovascular	$	432,124			$	378,493			$	347,430
	Endoscopy	16,925				15,795				12,019
	Total revenues	449,049				394,288				359,449
	Operating expenses
	Cardiovascular	157,479				142,089				122,600
	Endoscopy	9,044				10,262				9,678
	Total operating expenses	166,523				152,351				132,278
	Operating income (loss)
	Cardiovascular	26,597				30,411				38,010
	Endoscopy	1,247				(770		)		(4,820		)
	Total operating income	27,844				29,641				33,190
	Total other expense - net	(8,005		)		(2,023		)		(315		)
	Income tax expense	3,269				7,908				9,831
	Net income	$	16,570			$	19,710			$	23,044
Reconciliation of Assets from Segment to Consolidated	'
	Total assets by business segment at December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cardiovascular	$	716,659			$	692,689			$	434,747
	Endoscopy	11,624				12,620				12,270
	Total	$	728,283			$	705,309			$	447,017
Segment Depreciation And Amortization	'
	Total depreciation and amortization by business segment for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cardiovascular	$	31,594			$	21,441			$	18,219
	Endoscopy	948				1,093				975
	Total	$	32,542			$	22,534			$	19,194
Segment Capital Expenditures	'
	Total capital expenditures by business segment for the years ended December 31, 2013, 2012 and 2011, consisted of the following (in thousands):
		2013				2012				2011
	Cardiovascular	$	59,421			$	64,059			$	58,775
	Endoscopy	84				584				420
	Total	$	59,505			$	64,643			$	59,195

Quarterly_Results_of_Operation1

Quarterly Results of Operations (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of Quarterly Financial Information	'
	Quarterly data for the years ended December 31, 2013 and 2012 consisted of the following (in thousands, except per share amounts):
		Quarter Ended
		March 31			June 30		September 30		December 31
	2013
	Net sales	$	103,948		$	109,875	$	115,210	$	120,016
	Gross profit	42,993			46,985		51,030		53,359
	Income from operations	1,757			6,780		8,391		10,916
	Income tax expense (benefit)	(459		)	1,253		833		1,642
	Net income	671			3,752		5,607		6,540
	Basic earnings per common share	0.02			0.09		0.13		0.15
	Diluted earnings per common share	0.02			0.09		0.13		0.15
	2012
	Net sales	$	95,618		$	100,532	$	95,907	$	102,231
	Gross profit	44,170			47,024		45,335		45,463
	Income from operations	8,007			8,222		9,082		4,330
	Income tax expense	2,169			2,719		1,811		1,209
	Net income	5,748			6,095		7,226		641
	Basic earnings per common share	0.14			0.14		0.17		0.02
	Diluted earnings per common share	0.14			0.14		0.17		0.01

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	'
	Our financial assets and (liabilities) carried at fair value measured on a recurring basis as of December 31, 2013 and 2012, consisted of the following (in thousands):
							Fair Value Measurements Using
			Total Fair				Quoted prices in			Significant other			Significant
			Value at				active markets			observable inputs			Unobservable inputs
	Description		31-Dec-13				(Level 1)			(Level 2)			(Level 3)
	Interest rate swap (1)		$	1,203			$	—		$	1,203		$	—
							Fair Value Measurements Using
			Total Fair				Quoted prices in			Significant other			Significant
			Value at				active markets			observable inputs			Unobservable inputs
	Description		31-Dec-12				(Level 1)			(Level 2)			(Level 3)
	Interest rate swap (1)		$	(1,788	)		$	—		$	(1,788	)	$	—
	(1)    The fair value of the interest rate swap is determined based on forward yield curves.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	'
	Changes in the fair value of our contingent consideration liability during the years ended December 31, 2013 and 2012, consisted of the following (in thousands):
		2013				2012
	Beginning balance	$	6,697			$	1,290
	Contingent consideration liability recorded as the result of acquisitions (see Note 2)	—				4,704
	Initial purchase price adjustments finalized over the period (see Note 2)	—				280
	Fair value adjustments recorded to (income) expense during the period	(4,094		)		480
	Contingent payments made	(77		)		(57		)
	Ending balance	$	2,526			$	6,697
Fair Value Inputs, Liabilities, Quantitative Information	'
	The recurring Level 3 measurement of our contingent consideration liability includes the following significant unobservable inputs at December 31, 2013 and 2012 (amount in thousands):
	Contingent consideration liability		Fair value at December 31, 2013				Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	2,282			Discounted cash flow		Discount rate	11% - 15%
									Probability of milestone payment	90%
									Projected year of payments	2014-2028
	Other payments		$	244			Discounted cash flow		Discount rate	5.40%
									Probability of milestone payment	100%
									Projected year of payments	2014-2016
	Contingent consideration liability		Fair value at December 31, 2012				Valuation technique		Unobservable inputs	Range
	Revenue-based payments		$	6,370			Discounted cash flow		Discount rate	10% - 14.5%
									Probability of milestone payment	90%
									Projected year of payments	2013-2028
	Other payments		$	327			Discounted cash flow		Discount rate	4.50%
									Probability of milestone payment	100%
									Projected year of payments	2013-2015

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Organization (Details)	12 Months Ended
	Dec. 31, 2013
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Number of Operating Segments	2

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Intangible Assets (Details)

0 Months Ended

12 Months Ended

Apr. 06, 2011

Aug. 21, 2012

Jan. 05, 2012

Dec. 20, 2013

Sep. 10, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Developed technology

Distribution agreements

Distribution agreements

License agreements and trademarks

License agreements and trademarks

Patents

Royalty agreements

Minimum

Minimum

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Maximum

Maximum

Customer lists

Developed technology

Distribution agreements

License agreements and trademarks

Covenant not to compete

Customer lists

Developed technology

Distribution agreements

License agreements and trademarks

Covenant not to compete

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life

'10 years

'10 years

'12 years

'4 years

'10 years

'17 years

'5 years

'2 years

'5 years

'4 years

'5 years

'3 years

'15 years

'15 years

'12 years

'15 years

'10 years

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies - Property and Equipment (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Depreciation	$18.40	$15	$13.20
Building	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'40 years	'	'
Minimum | Manufacturing equipment	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'4 years	'	'
Minimum | Furniture and fixtures	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'3 years	'	'
Minimum | Land improvements	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'10 years	'	'
Minimum | Leasehold improvements	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'4 years	'	'
Maximum | Manufacturing equipment	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'20 years	'	'
Maximum | Furniture and fixtures	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'20 years	'	'
Maximum | Land improvements	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'20 years	'	'
Maximum | Leasehold improvements	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Useful life	'25 years	'	'

Organization_and_Summary_of_Si6

Organization and Summary of Significant Accounting Policies - Deferred Compensation (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Cash Surrender Value of Life Insurance	$7,800,000	$6,100,000
Deferred Compensation Liability, Classified, Noncurrent	$7,833,000	$5,956,000

Organization_and_Summary_of_Si7

Organization and Summary of Significant Accounting Policies - Marketable Securities (Details) (USD $)	12 Months Ended
	Dec. 31, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Available-for-sale Securities, Amortized Cost Basis	$2,500,000
Marketable Securities, Noncurrent	2,800,000
Available-for-sale Securities, Gross Unrealized Gains	$295,000

Organization_and_Summary_of_Si8

Organization and Summary of Significant Accounting Policies - Other Assets (Details)	Dec. 31, 2013
	investment
Accounting Policies [Abstract]	'
Other Assets, Deferred Compensation Plan, Number of Investments, Cost Method	2

Organization_and_Summary_of_Si9

Organization and Summary of Significant Accounting Policies - Stock Based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'
Allocated Share-based Compensation Expense	$1,467	$1,917	$1,644

Recovered_Sheet1

Organization and Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]	'	'	'
Concentration Risk, Percentage	3.00%	4.00%	4.00%

Recovered_Sheet2

Organization and Summary of Significant Accounting Policies - Accumulated Other Comprehensive Income (Loss) (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Accumulated other comprehensive income (loss), interest rate swaps, net of tax	$735,000	'
Accumulated other comprehensive income (loss), interest rate swap, tax benefit	-468,000	-1,788,000
Accumulated other comprehensive income (loss) related to foreign currency translation, net of tax	208,000	-89,000
Accumulated other comprehensive income (loss), foreign currency translation, tax benefit	12,000	-7,000
Accumulated other comprehensive income (loss), marketable securities, net of tax	'	-1,100,000
Accumulated other comprehensive income (Loss), marketable securities, tax	'	$696,000

Acquisitions_Purchase_Price_Al

Acquisitions - Purchase Price Allocation (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Oct. 04, 2013

Oct. 04, 2013

Jan. 31, 2012

Nov. 19, 2012

Dec. 19, 2012

Sep. 02, 2011

Oct. 04, 2013

Oct. 04, 2013

Jan. 31, 2012

Nov. 19, 2012

Dec. 19, 2012

Sep. 02, 2011

Oct. 04, 2013

Oct. 04, 2013

Jan. 31, 2012

Nov. 19, 2012

Dec. 19, 2012

Sep. 02, 2011

Oct. 04, 2013

Oct. 04, 2013

Jan. 31, 2012

Nov. 19, 2012

Dec. 19, 2012

Jan. 31, 2012

Nov. 19, 2012

Dec. 19, 2012

In Thousands, unless otherwise specified

Radial Assist

Datascope

Ostial Solutions, LLC

MediGroup

Thomas Medical Products, Inc

Ash

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Customer lists

Customer lists

Customer lists

Customer lists

Customer lists

Customer lists

Trademarks

Trademarks

Trademarks

Trademarks

Trademarks

Non-compete agreements

Non-compete agreements

Non-compete agreements

Radial Assist

Datascope

Ostial Solutions, LLC

MediGroup

Thomas Medical Products, Inc

Ash

Radial Assist

Datascope

Ostial Solutions, LLC

MediGroup

Thomas Medical Products, Inc

Ash

Radial Assist

Datascope

Ostial Solutions, LLC

MediGroup

Thomas Medical Products, Inc

Ostial Solutions, LLC

MediGroup

Thomas Medical Products, Inc

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Trade receivables

'

'

'

'

'

'

'

$6,507

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventories

'

'

'

16

478

'

263

5,459

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prepaid expenses

'

'

'

'

'

'

'

340

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Property and equipment

'

'

'

'

'

'

79

2,685

73

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangibles

'

'

'

'

'

'

'

'

'

1,520

18,200

10,500

2,000

43,000

3,200

20

390

600

110

5,000

300

40

320

110

80

1,400

10

210

500

Goodwill

184,505

175,108

61,144

904

8,112

9,580

1,697

102,407

2,697

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets acquired

'

'

'

2,500

27,500

20,800

4,439

167,298

6,270

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts payable

'

'

'

'

'

'

'

588

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued expenses

'

'

'

'

'

'

'

1,094

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total liabilities assumed

'

'

'

'

'

'

'

1,682

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net assets acquired, net of cash acquired

'

'

'

'

'

'

'

165,616

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash acquired

'

'

'

'

'

'

'

$1,829

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisitions_Pro_Forma_Consoli

Acquisitions - Pro Forma Consolidated Results (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$120,016	$115,210	$109,875	$103,948	$102,231	$95,907	$100,532	$95,618	$449,049	$394,288	$359,449
Sales, Pro Forma	'	'	'	'	'	'	'	'	454,333	438,981	396,767
Net income	'	'	'	'	'	'	'	'	16,570	19,710	23,044
Net income, Pro Forma	'	'	'	'	'	'	'	'	$17,112	$25,075	$22,033
EARNINGS PER COMMON SHARE:	'	'	'	'	'	'	'	'	'	'	'
Earnings per common share: basic (in dollars per share)	$0.15	$0.13	$0.09	$0.02	$0.02	$0.17	$0.14	$0.14	$0.39	$0.47	$0.59
Earnings per common share: basic, Pro Forma (in dollars per share)	'	'	'	'	'	'	'	'	$0.40	$0	$0.56
Earnings per common share: diluted (in dollars per share)	$0.15	$0.13	$0.09	$0.02	$0.01	$0.17	$0.14	$0.14	$0.39	$0.46	$0.58
Earnings per common share: diluted, Pro Forma (in dollars per share)	'	'	'	'	'	'	'	'	$0.40	$0	$0.55

Acquisitions_Narrative_Details

Acquisitions - Narrative (Details) (USD $)

3 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 19, 2012

Dec. 31, 2013

Dec. 31, 2012

Nov. 19, 2012

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2012

Aug. 31, 2012

Jan. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Sep. 02, 2011

Sep. 30, 2011

Dec. 31, 2013

Dec. 31, 2012

Oct. 04, 2013

Dec. 31, 2013

Dec. 31, 2013

Apr. 06, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Sep. 10, 2010

Dec. 31, 2010

Dec. 31, 2010

Aug. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 20, 2013

Sep. 10, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 10, 2010

Dec. 31, 2013

Dec. 31, 2012

Jan. 05, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Aug. 27, 2012

Aug. 21, 2012

Jan. 05, 2012

31-May-12

Jan. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Aug. 07, 2012

31-May-12

Dec. 31, 2011

Jul. 31, 2011

Jun. 30, 2011

Dec. 31, 2012

Dec. 15, 2011

Jul. 18, 2011

Jun. 20, 2011

Dec. 31, 2012

Dec. 31, 2012

Dec. 19, 2012

Sep. 10, 2010

Aug. 07, 2012

Thomas Medical Products, Inc

Thomas Medical Products, Inc

Thomas Medical Products, Inc

MediGroup

MediGroup

MediGroup

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ostial Solutions, LLC

Ash

Ash

Ash

Ash

Datascope

Datascope

Radial Assist

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed technology

Developed Technology Rights, Acquired in August 2011, Two

Non-compete agreements

Non-compete agreements

Non-compete agreements

Non-compete agreements

Non-compete agreements

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

License agreements and trademarks

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Customer Lists

Trademarks

Trademarks

Trademarks

Trademarks

Trademarks

Trademarks

Trademarks

License Agreement Terms

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Distribution agreements

Blockade Medical LLC

Intellectual Property Rights

Intellectual Property Rights

Intellectual Property Rights

Intellectual Property Rights

Intellectual Property Rights

Intellectual Property Rights

Intellectual Property Rights

Intellectual Property Rights

Development of Biomaterial Technology

Covered Biliary In-Process Research and Development

Wells Fargo Credit Agreement

Wells Fargo Credit Agreement

Special Membership Units

Thomas Medical Products, Inc

MediGroup

Ostial Solutions, LLC

Ash

BioSphere

Datascope

Radial Assist

Thomas Medical Products, Inc

MediGroup

Ostial Solutions, LLC

Thomas Medical Products, Inc

MediGroup

Ostial Solutions, LLC

Ash

Datascope

Radial Assist

Thomas Medical Products, Inc

MediGroup

Ostial Solutions, LLC

Datascope

Radial Assist

Blockade Medical LLC

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

$120,016,000

$115,210,000

$109,875,000

$103,948,000

$102,231,000

$95,907,000

$100,532,000

$95,618,000

$449,049,000

$394,288,000

$359,449,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to acquire businesses

'

'

'

'

'

'

'

'

'

'

'

167,000,000

'

'

4,000,000

'

'

'

6,500,000

10,000,000

'

'

'

5,000,000

'

'

27,500,000

'

2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income before tax

'

'

'

'

'

'

'

'

'

'

'

'

'

51,000

'

'

'

'

'

'

'

'

'

'

'

'

'

1,600,000

191,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful life

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'8 years

'8 years

'15 years

'15 years

'

'10 years

'10 years

'

'

'

'3 years

'7 years

'5 years

'4 years

'10 years

'

'

'

'

'

'

'12 years

'8 years

'8 years

'2 years

'6 years

'6 years

'

'

'15 years

'15 years

'15 years

'15 years

'15 years

'3 years

'10 years

'12 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average useful life

'

'

'

'

'

'

'

'

'

'

'

'

'8 years 6 months 18 days

'

'

'8 years 1 month 24 days

'

'

'

'

'14 years 7 months 6 days

'

'

'

'9 years

'

'

'10 years

'10 years 0 months 27 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term debt issuance costs

'

'

'

'

'

'

'

'

798,000

3,706,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,700,000

798,000

'

Payments to acquire intangible assets

'

'

'

'

'

'

'

'

1,617,000

1,460,000

2,077,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

500,000

'

'

500,000

'

'

'

'

'

350,000

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

750,000

250,000

'

1,000,000

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Liabilities, Current

27,702,000

'

'

'

27,269,000

'

'

'

27,702,000

27,269,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

350,000

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Finite-Lived Intangible Assets, Gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,029,000

1,035,000

'

'

'

700,000

250,000

3,783,000

2,733,000

'

20,626,000

20,468,000

'

'

'

'

'

'

'

7,622,000

7,311,000

'

'

'

'

'

'

'

'

'

'

5,176,000

5,176,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued Liability, Current, Due Date in Relation to First Commercial Sale

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities incurred

'

'

'

'

'

'

'

'

'

'

'

'

'

445,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales

'

'

'

'

'

'

'

'

'

'

'

'

'

1,900,000

'

'

169,000

'

'

'

'

457,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Period Increase (Decrease)

'

'

'

'

'

'

'

'

'

'

'

'

381,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired receivables

'

'

'

'

'

'

'

'

'

'

'

6,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated uncollectible trade receivables acquired

'

'

'

'

'

'

'

'

'

'

'

34,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-related costs

'

'

'

'

'

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, payment, 2013

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, payment, 2014

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, payment, 2015

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2016

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2017

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2018

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2019

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2021

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment, 2022

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential payment, annual increase in net sales, minimum percent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

403,000

'

'

4,300,000

'

4,300,000

'

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets purchased

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

91,052,000

87,332,000

'

'

'

'

'

'

'

'

630,000

875,000

'

'

'

'

'

2,534,000

1,872,000

'

9,669,000

12,430,000

95,000

'

'

'

'

'

'

5,778,000

5,949,000

'

'

'

'

'

750,000

250,000

2,500,000

'

'

3,396,000

3,875,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contingent consideration, potential payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,500,000

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost method investments, special membership units

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

422,594

Cost method investments, ownership percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments to Acquire Investments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquired in-process research and development

'

'

'

'

'

'

'

'

0

2,450,000

5,838,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

2,000,000

1,000,000

1,000,000

4,900,000

'

'

'

500,000

400,000

'

'

'

Adjustment related to previous acquisitions

'

'

'

'

'

'

'

'

381,000

280,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

280,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development, contingent consideration, liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

1,000,000

3,500,000

'

'

'

'

'

Research and development, contingent consideration, discounted liability

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$968,000

'

'

$989,000

'

'

'

'

'

'

'

'

Inventories_Details

Inventories (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished goods	$43,364	$48,233
Work-in-process	6,222	6,051
Raw materials	32,792	30,315
Total	$82,378	$84,599

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Goodwill (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill [Line Items]	'	'
Accumulated impairment loss	$8,344	'
Goodwill [Roll Forward]	'	'
Goodwill balance at January 1	175,108	61,144
Adjustment related to previous acquisitions	381	280
Additions as the result of acquisitions	9,016	113,684
Goodwill balance at December 31	$184,505	$175,108

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Other Intangible Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Aug. 21, 2012	Jan. 05, 2012	Dec. 31, 2013	Dec. 20, 2013	Sep. 10, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Jan. 05, 2012	Dec. 31, 2013	Dec. 31, 2012
	Other	Other	Patents	Patents	Distribution agreements	Distribution agreements	Distribution agreements	Distribution agreements	License agreements and trademarks	License agreements and trademarks	License agreements and trademarks	License agreements and trademarks	Trademarks	Trademarks	Non-compete agreements	Non-compete agreements	Customer lists	Customer lists	Customer lists	Royalty agreements	Royalty agreements
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Finite-Lived Intangible Assets, Gross	$47,805,000	$44,833,000	$9,302,000	$7,843,000	$5,176,000	$5,176,000	'	'	$3,783,000	$700,000	$250,000	$2,733,000	$7,622,000	$7,311,000	$1,029,000	$1,035,000	$20,626,000	$20,468,000	'	$267,000	$267,000
Accumulated Amortization	-18,870,000	-14,034,000	-2,374,000	-2,045,000	-1,780,000	-1,301,000	'	'	-1,249,000	'	'	-861,000	-1,844,000	-1,362,000	-399,000	-160,000	-10,957,000	-8,038,000	'	-267,000	-267,000
Net Carrying Amount	$28,935,000	$30,799,000	$6,928,000	$5,798,000	$3,396,000	$3,875,000	$250,000	$2,500,000	$2,534,000	'	'	$1,872,000	$5,778,000	$5,949,000	$630,000	$875,000	$9,669,000	$12,430,000	$95,000	$0	$0

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Future Amortization Expense (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
2014	$15,189
2015	14,751
2016	14,094
2017	13,678
2018	$13,158

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Narrative (Details) (USD $)	12 Months Ended			3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 30, 2013	Dec. 31, 2013
				Ostial Solutions, LLC	Thomas Medical Products, Inc
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Goodwill, Period Increase (Decrease)	'	'	'	'	$381,000
Goodwill impairment charge	8,089,000	'	'	'	'
Accumulated impairment loss	8,344,000	'	'	'	'
Aggregate amortization expense	14,200,000	7,500,000	6,000,000	'	'
Intangible asset impairment charges	8,089,000	0	0	8,100,000	'
Contingent consideration benefit	'	'	'	$3,800,000	'

Income_Taxes_Domestic_and_Fore

Income Taxes - Domestic and Foreign (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Domestic	'	'	'	'	'	'	'	'	$5,435	$15,958	$21,123
Foreign	'	'	'	'	'	'	'	'	14,404	11,660	11,752
INCOME BEFORE INCOME TAXES	$10,916	$8,391	$6,780	$1,757	$4,330	$9,082	$8,222	$8,007	$19,839	$27,618	$32,875

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense (Benefit) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current expense (benefit):	'	'	'	'	'	'	'	'	'	'	'
Federal	'	'	'	'	'	'	'	'	($747)	$5,350	$5,662
State	'	'	'	'	'	'	'	'	333	1,014	1,001
Foreign	'	'	'	'	'	'	'	'	2,324	995	1,491
Total current expense	'	'	'	'	'	'	'	'	1,910	7,359	8,154
Deferred expense (benefit):	'	'	'	'	'	'	'	'	'	'	'
Federal	'	'	'	'	'	'	'	'	1,089	871	1,121
State	'	'	'	'	'	'	'	'	278	-343	74
Foreign	'	'	'	'	'	'	'	'	-8	21	482
Total deferred expense	'	'	'	'	'	'	'	'	1,359	549	1,677
Total	$1,642	$833	$1,253	($459)	$1,209	$1,811	$2,719	$2,169	$3,269	$7,908	$9,831

Income_Taxes_Effective_Income_

Income Taxes - Effective Income Tax Rate Reconciliation (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Computed federal income tax expense at statutory rate of 35%	'	'	'	'	'	'	'	'	$6,943	$9,667	$11,506
State income taxes	'	'	'	'	'	'	'	'	397	436	699
Tax credits	'	'	'	'	'	'	'	'	-1,385	-779	-778
Production activity deduction	'	'	'	'	'	'	'	'	0	-388	-425
Foreign tax rate differential	'	'	'	'	'	'	'	'	-2,374	-1,419	-1,297
Uncertain tax positions	'	'	'	'	'	'	'	'	-520	-42	281
Deferred compensation insurance assets	'	'	'	'	'	'	'	'	-358	-155	88
Other — including the effect of graduated rates	'	'	'	'	'	'	'	'	566	588	-243
Total	$1,642	$833	$1,253	($459)	$1,209	$1,811	$2,719	$2,169	$3,269	$7,908	$9,831

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets and Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]	'	'
Net Operating Loss Carryforwards Used In The Current Period	$3,800,000	$8,600,000
Deferred income tax assets:	'	'
Allowance for uncollectible accounts receivable	342,000	348,000
Accrued compensation expense	5,001,000	3,954,000
Inventory differences	2,317,000	1,949,000
Net operating loss carry-forwards	18,060,000	19,622,000
Deferred revenue	280,000	237,000
Stock-based compensation expense	2,704,000	2,465,000
Uncertain tax positions	559,000	709,000
Federal research and development credit carry-forward	569,000	0
Other	3,197,000	3,762,000
Total deferred income tax assets	33,029,000	33,046,000
Deferred income tax liabilities:	'	'
Prepaid expenses	-751,000	-757,000
Property and equipment	-21,893,000	-19,001,000
Intangible assets	-3,837,000	-4,107,000
Other	-1,295,000	-1,116,000
Total deferred income tax liabilities	-27,776,000	-24,981,000
Valuation allowance	-1,363,000	-1,225,000
Net deferred income tax assets	3,890,000	6,840,000
Reported as:	'	'
Deferred income tax assets - Current	5,638,000	4,976,000
Deferred income tax assets - Long-term	800,000	4,237,000
Deferred income tax liabilities - Long-term	($2,548,000)	($2,373,000)

Income_Taxes_Summary_of_Income

Income Taxes - Summary of Income Tax Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Unrecognized tax benefits, opening balance	$2,776,000	$3,113,000	$2,952,000
Gross increases in tax positions taken in a prior year	107,000	83,000	347,000
Gross increases in tax positions taken in the current year	236,000	260,000	865,000
Settlements with taxing authorities	0	0	-507,000
Lapse of applicable statute of limitations	-990,000	-680,000	-544,000
Unrecognized tax benefits, ending balance	$2,129,000	$2,776,000	$3,113,000

Income_Taxes_Narrative_Details

Income Taxes - Narrative (Details) (USD $)	3 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Disclosure [Abstract]	'	'	'	'	'	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	'	'	$138,000	$864,000	$361,000	'
U.S federal net operating loss carryforwards	52,000,000	56,000,000	52,000,000	56,000,000	'	'
Net Operating Loss Carryforwards Utilization	'	'	'13 years	'	'	'
Net Operating Loss Carryforwards Used In The Current Period	'	'	3,800,000	8,600,000	'	'
non-U.S. net operating loss carryforwards	125,000	150,000	125,000	150,000	'	'
Tax Credit Research And Development	'	'	600,000	'	'	'
Unrecognized Tax Benefits Gross Including Interest and Penalties	2,300,000	2,900,000	2,300,000	2,900,000	'	'
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,700,000	2,200,000	1,700,000	2,200,000	'	'
Deferred Tax Asset, Reduction in Valuation Allowance, Noncurrent	'	'	236,000	'	'	'
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	'	139,000	'	139,000	161,000	'
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense	'	'	22,000	215,000	'	12,000
Settlements with taxing authorities	'	'	0	0	-507,000	'
Estimated change in unrecognized tax benefit in next twelve months, lower bound	200,000	'	200,000	'	'	'
Estimated change in unrecognized tax benefit in next twelve months, upper bound	$600,000	'	$600,000	'	'	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%	'	'	35.00%	'

Accrued_Expenses_Details

Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Payroll taxes	$1,816	$1,893
Payroll	3,474	3,141
Bonuses	5,273	5,778
Commissions	984	894
Vacation	6,280	5,066
Royalties	1,221	1,368
Value-added tax	1,469	1,158
Other accrued expenses	7,185	7,971
Total	$27,702	$27,269

Revolving_Credit_Facility_and_2

Revolving Credit Facility and Long-Term Debt - Narrative (Details) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 19, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Oct. 04, 2013

Sep. 30, 2010

Dec. 19, 2012

Dec. 31, 2013

Dec. 19, 2012

Dec. 31, 2013

Credit Agreement

Credit Agreement

Base Rate

Base Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

London Interbank Offered Rate (LIBOR)

London Interbank Offered Rate (LIBOR)

Federal Funds Rate

Variable Rate 1

Variable Rate 1

Variable Rate 2

Variable Rate 2

Revolving Credit Facility

Revolving Credit Facility

Term Loan

Bridge Loan

Bridge Loan

Bridge Loan

quarter

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Credit Agreement

Wells Fargo

Credit Agreement

Base Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

London Interbank Offered Rate (LIBOR) Market Index Rate

Credit Agreement

Credit Agreement

Credit Agreement

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Amount Outstanding

$248,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

'

'

'

'

'

'

'

215,000,000

125,000,000

100,000,000

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

1.00%

0.25%

2.00%

1.25%

2.00%

1.25%

'

'

'

'

'

'

'

'

'

2.00%

1.25%

Debt Instrument, Basis Spread on Base Rate

'

'

'

'

'

'

'

0.01

0.005

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Current Quarter, Maximum

4.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter One, Maximum

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Two, Maximum

3.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Three, Maximum

3.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Quarter Four, Maximum

3.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Two, Maximum

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Three, Maximum

2.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Year Four, Maximum

2.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated EBITDA to Fixed Charges Ratio, Number of Consecutive Quarters

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated EBITDA to Fixed Charges Ratio, Minimum

1.75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Net Income, Maximum

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Facility Capital Expenditures, Next Twelve Months, Maximum

30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Covenant Terms, Consolidated Total Leverage Ratio, Minimum

'

'

'

2.25

'

2.25

'

2.25

'

'

'

'

'

'

'

'

2.25

'

'

Line of Credit Facility, Remaining Borrowing Capacity

34,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate

4.23%

2.98%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Fixed Interest, Amount

145,000,000

150,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate

'

'

'

'

'

'

'

'

'

3.42%

2.22%

3.50%

2.31%

'

'

'

'

'

'

Long-term Debt, Percentage Bearing Variable Interest, Amount

'

'

'

'

'

'

'

'

'

$101,500,000

$87,000,000

$2,354,000

$566,000

'

'

'

'

'

'

Revolving_Credit_Facility_and_3

Revolving Credit Facility and Long-Term Debt - Principal Balances under Long-term Debt (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Line of Credit Facility [Line Items]	'	'
Total long-term debt	$248,854	$237,566
Less current portion	10,000	10,000
Long-term portion	238,854	227,566
Term Loan	'	'
Line of Credit Facility [Line Items]	'	'
Total long-term debt	92,500	100,000
Revolving Credit Facility	'	'
Line of Credit Facility [Line Items]	'	'
Total long-term debt	$156,354	$137,566

Revolving_Credit_Facility_and_4

Revolving Credit Facility and Long-Term Debt - Future Minimum Payments on Long-term Debt (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
2014	$10,000	'
2015	10,000	'
2016	10,000	'
2017	218,854	'
Total long-term debt	$248,854	$237,566

Derivatives_Interest_Rate_Swap

Derivatives - Interest Rate Swap (Details) (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 19, 2012
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'	'	'	'
Derivative, Fixed Interest Rate	'	'	'	0.98%
Interest rate swap	'	($1,200,000)	($700,000)	'
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Tax	'	468,000	1,788,000	'
Notional Amount of Interest Rate Cash Flow Hedge Derivatives	55,000,000	'	'	150,000,000
Derivative, Cash Received on Hedge	$28,000	'	'	'

Derivatives_Foreign_Currency_F

Derivatives - Foreign Currency Forward Contracts (Details)	12 Months Ended			0 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Nov. 29, 2013	Nov. 30, 2012	Nov. 29, 2013	Nov. 30, 2012
	USD ($)	USD ($)	USD ($)	30 Day Forward Contract EURO	30 Day Forward Contract EURO	30 Day Forward Contract GBP	30 Day Forward Contract GBP
				EUR (€)	EUR (€)	GBP (£)	GBP (£)
Derivatives, Fair Value [Line Items]	'	'	'	'	'	'	'
Forward Contract Term	'	'	'	'30 days	'30 days	'30 days	'30 days
Derivative, Notional Amount	'	'	'	€ 494	€ 527	£ 847	£ 565
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	($202)	($11)	$221	'	'	'	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
2014	$6,569
2015	5,956
2016	4,974
2017	4,122
2018	4,073
Thereafter	36,067
Total minimum lease payments	$61,761

Commitments_and_Contingencies_2

Commitments and Contingencies (Details) (USD $)	3 Months Ended		12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'	'
Proceeds from sale-leaseback transaction	$24,000,000	'	$24,000,000	$0	$0
Lessee Leasing Arrangements, Operating Leases, Term of Contract	'	'19 years 10 months	'	'	'
Operating Leases, Rent Expense	'	'	5,500,000	4,800,000	4,100,000
Irish Grants Related to Research and Development, Training and Hiring	'	'	1,176,000	424,000	261,000
Deferred Credits and Other Liabilities	3,100,000	3,000,000	3,100,000	3,000,000	'
Irish Grants Related to Purchased Property Plant and Equipment	'	'	139,000	174,000	106,000
Refundable Irish Grants if Operations Cease	$5,000,000	'	$5,000,000	'	'

Earnings_Per_Common_Share_EPS_1

Earnings Per Common Share (EPS) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Earnings Per Share, Basic and Diluted [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net Income, Basic EPS	'	'	'	'	'	'	'	'	$16,570	$19,710	$23,044
Shares, Basic EPS	'	'	'	'	'	'	'	'	42,607,000	42,176,000	39,086,000
Basic (in dollars per share)	$0.15	$0.13	$0.09	$0.02	$0.02	$0.17	$0.14	$0.14	$0.39	$0.47	$0.59
Effect of dilutive stock options and warrants	'	'	'	'	'	'	'	'	277,000	434,000	647,000
Net Income, Diluted EPS	'	'	'	'	'	'	'	'	$16,570	$19,710	$23,044
Shares, Diluted EPS	'	'	'	'	'	'	'	'	42,884,000	42,610,000	39,733,000
Diluted (in dollars per share)	$0.15	$0.13	$0.09	$0.02	$0.01	$0.17	$0.14	$0.14	$0.39	$0.46	$0.58
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	'	'	'	'	'	'	1,823,000	1,588,000	909,000

Employee_Stock_Purchase_Plan_S2

Employee Stock Purchase Plan Stock Options and Warrants - Long Term Incentive Plans (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
2006 Incentive Plan	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	1,100
Employee Stock Purchase Plan Qualified	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	229
Share Based Compensation Arrangement Employee Stock Purchase Plan Percentage of Market Price Purchase Date	95.00%
Employee Stock Purchase Plan Non Qualified	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	60
Stock Options | 2006 Incentive Plan | Minimum	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting period	'3 years
Stock Option Contractual Life	'7 years
Stock Options | 2006 Incentive Plan | Maximum	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting period	'5 years
Stock Option Contractual Life	'10 years
Performance Shares | 2006 Incentive Plan	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Award vesting period	'1 year

Employee_Stock_Purchase_Plan_S3

Employee Stock Purchase Plan Stock Options and Warrants - Allocation of Recognized Period Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$1,467,000	$1,917,000	$1,644,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	4,200,000	'	'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	'3 years 3 months 11 days	'	'
Cost of goods sold	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	145,000	245,000	241,000
Research and development	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	87,000	119,000	86,000
Selling, general, and administrative	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'
Allocated Share-based Compensation Expense	$1,235,000	$1,553,000	$1,317,000

Employee_Stock_Purchase_Plan_S4

Employee Stock Purchase Plan Stock Options and Warrants - Fair Value Calculation Assumptions (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Risk-free interest rate, minimum	0.65%	0.54%	0.68%
Risk-free interest rate, maximum	1.16%	0.95%	'
Risk-free interest rate	'	'	1.34%
Expected option life	'	'	'6 years
Expected dividend yield	0.00%	0.00%	0.00%
Expected price volatility, minimum	34.08%	42.01%	'
Expected price volatility, maximum	41.67%	44.56%	'
Expected price volatility	'	'	45.29%
Stock-based compensation grants	348	128	844
Stock-based compensation grants, total fair value	$1,400	$700	$4,300
Minimum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected option life	'4 years 2 months 12 days	'4 years 2 months 12 days	'4 years 2 months 12 days
Expected price volatility	'	'	42.11%
Maximum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected option life	'6 years	'6 years	'

Employee_Stock_Purchase_Plan_S5

Employee Stock Purchase Plan Stock Options and Warrants - Stock Option Activity (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'
Total intrinsic value of stock options exercised	$1,649	$3,472	$9,433
Cash received from stock option exercises	3,281	3,325	7,197
Excess tax benefit from the exercise of stock options	259	877	3,122
Number of Shares	'	'	'
Beginning balance (in shares)	3,535	'	'
Granted (in shares)	348	128	844
Exercised (in shares)	-368	'	'
Forfeited/expired (in shares)	-507	'	'
Outstanding at December 31 (in shares)	3,008	3,535	'
Exercisable (in shares)	2,075	'	'
Ending vested and expected to vest (in shares)	2,991	'	'
Weighted Average Exercise Price	'	'	'
Beginning balance (in dollars per share)	$12.14	$12.55	'
Granted (in dollars per share)	$12.08	'	'
Exercised (in shares)	$10.10	'	'
Forfeited/expired (in shares)	$16.43	'	'
Outstanding at December 31 (in dollars per share)	$12.14	$12.55	'
Exercisable (in dollars per share)	$11.73	'	'
Ending vested and expected to vest (in dollars per share)	$12.14	'	'
Outstanding, Remaining Contractual Term	'2 years 11 months 1 day	'	'
Outstanding, Intrinsic Value	10,823	'	'
Exercisable, Remaining Contractual Term	'1 year 10 months 10 days	'	'
Exercisable, Intrinsic Value	8,312	'	'
Ending vested and expected to vest, Remaining Contractual Term	'2 years 10 months 29 days	'	'
Ending vested and expected to vest, Intrinsic Value	$10,772	'	'
Weighted average grant-date fair value of options granted	$4.01	$5.31	$5.28

Employee_Stock_Purchase_Plan_S6

Employee Stock Purchase Plan Stock Options and Warrants - Options Outstanding (Details) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise	$9.58
Range of Exercise	$15.12
Number Outstanding	3,008
Number Exercisable	2,075
$7.65 - $9.70	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise	$9.58
Range of Exercise	$11.05
Number Outstanding	764
Weighted Average Remaining Contractual Life (in years)	'1 year 11 months 5 days
Weighted Average Exercise Price	$9.96
Number Exercisable	639
Weighted Average Exercise Price	$9.97
$9.71 - $11.53	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise	$11.41
Range of Exercise	$12.02
Number Outstanding	859
Weighted Average Remaining Contractual Life (in years)	'1 year 3 months 0 days
Weighted Average Exercise Price	$11.68
Number Exercisable	859
Weighted Average Exercise Price	$11.68
$12.02 - $13.75	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise	$12.10
Range of Exercise	$13.75
Number Outstanding	1,094
Weighted Average Remaining Contractual Life (in years)	'4 years 10 months 24 days
Weighted Average Exercise Price	$13.53
Number Exercisable	367
Weighted Average Exercise Price	$13.60
$13.82 - $17.34	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Range of Exercise	$13.77
Range of Exercise	$15.12
Number Outstanding	291
Weighted Average Remaining Contractual Life (in years)	'3 years 0 months 0 days
Weighted Average Exercise Price	$14.03
Number Exercisable	210
Weighted Average Exercise Price	$14.08

Segment_Reporting_and_Foreign_2

Segment Reporting and Foreign Operations - Sales by Business Segment (Details) (USD $)

3 Months Ended

12 Months Ended

In Thousands, unless otherwise specified

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

$120,016

$115,210

$109,875

$103,948

$102,231

$95,907

$100,532

$95,618

$449,049

$394,288

$359,449

'

% Change

13.89%

'

'

'

10.00%

'

'

'

13.89%

10.00%

'

21.00%

Cardiovascular Segment

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

432,124

378,493

347,430

'

% Change

14.17%

'

'

'

9.00%

'

'

'

14.17%

9.00%

'

21.00%

Cardiovascular Segment | Stand Alone Devices

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

125,445

114,242

101,959

'

% Change

9.81%

'

'

'

12.05%

'

'

'

9.81%

12.05%

'

15.00%

Cardiovascular Segment | Custom Kit And Procedures Trays

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

103,700

94,586

91,532

'

% Change

9.64%

'

'

'

3.34%

'

'

'

9.64%

3.34%

'

11.00%

Cardiovascular Segment | Inflation Devices

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

66,182

68,979

67,353

'

% Change

-4.05%

'

'

'

2.41%

'

'

'

-4.05%

2.41%

'

8.00%

Cardiovascular Segment | Catheters

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

75,131

64,878

55,357

'

% Change

15.80%

'

'

'

17.20%

'

'

'

15.80%

17.20%

'

23.00%

Cardiovascular Segment | Embolization Devices

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

33,395

33,870

31,229

'

% Change

-1.40%

'

'

'

8.46%

'

'

'

-1.40%

8.46%

'

247.00%

Cardiovascular Segment | Electrophysiology

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

28,271

1,938

0

'

% Change

1358.77%

'

'

'

0.00%

'

'

'

1358.77%

0.00%

'

0.00%

Endoscopy Segment

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

16,925

15,795

12,019

'

Endoscopy Segment | Endoscopy Devices

'

'

'

'

'

'

'

'

'

'

'

'

Revenue from External Customer [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

$16,925

$15,795

$12,019

'

% Change

7.15%

'

'

'

31.00%

'

'

'

7.15%

31.00%

'

33.00%

Segment_Reporting_and_Foreign_3

Segment Reporting and Foreign Operations - Foreign Sales (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'
Foreign Sales Percent of Total Sales	37.00%	37.00%	35.00%
Foreign Sales	'	'	'
Segment Reporting Information [Line Items]	'	'	'
Revenue, Net	$166	$146.30	$125.90

Segment_Reporting_and_Foreign_4

Segment Reporting and Foreign Operations - Long-lived Assets by Geographic Area (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Long-Lived Assets	$243,270	$234,803	$179,140
United States	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Long-Lived Assets	178,130	176,644	134,393
Ireland	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Long-Lived Assets	50,274	48,182	36,008
Other Foreign Countries	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Long-Lived Assets	$14,866	$9,977	$8,739

Segment_Reporting_and_Foreign_5

Segment Reporting and Foreign Operations - Operating Income (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	$120,016	$115,210	$109,875	$103,948	$102,231	$95,907	$100,532	$95,618	$449,049	$394,288	$359,449
Operating expenses	'	'	'	'	'	'	'	'	166,523	152,351	132,278
Impairment of goodwill	'	'	'	'	'	'	'	'	8,089	'	'
Operating income (loss)	'	'	'	'	'	'	'	'	27,844	29,641	33,190
Total other expense - net	'	'	'	'	'	'	'	'	-8,005	-2,023	-315
Income tax expense	1,642	833	1,253	-459	1,209	1,811	2,719	2,169	3,269	7,908	9,831
NET INCOME	'	'	'	'	'	'	'	'	16,570	19,710	23,044
Cardiovascular Segment	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	432,124	378,493	347,430
Operating expenses	'	'	'	'	'	'	'	'	157,479	142,089	122,600
Operating income (loss)	'	'	'	'	'	'	'	'	26,597	30,411	38,010
Endoscopy Segment	'	'	'	'	'	'	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Revenues	'	'	'	'	'	'	'	'	16,925	15,795	12,019
Operating expenses	'	'	'	'	'	'	'	'	9,044	10,262	9,678
Operating income (loss)	'	'	'	'	'	'	'	'	$1,247	($770)	($4,820)

Segment_Reporting_and_Foreign_6

Segment Reporting and Foreign Operations - Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Assets	$728,283	$705,309	$447,017
Depreciation and amortization	32,542	22,534	19,194
Capital expenditures	59,505	64,643	59,195
Cardiovascular Segment	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Assets	716,659	692,689	434,747
Depreciation and amortization	31,594	21,441	18,219
Capital expenditures	59,421	64,059	58,775
Endoscopy Segment	'	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'	'
Assets	11,624	12,620	12,270
Depreciation and amortization	948	1,093	975
Capital expenditures	$84	$584	$420

Royalty_Agreements_Details

Royalty Agreements (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Datascope Royalty Agreement	'	'	'
Royalty Agreements [Line Items]	'	'	'
Current Royalty Rate	5.00%	'	'
Minimum Royalty Payment	$50,000	'	'
Royalty Expense	50,000	'	'
BioSphere APHP Royalty	'	'	'
Royalty Agreements [Line Items]	'	'	'
Current Royalty Rate	5.00%	'	'
Future Royalty Rate	2.50%	'	'
Royalty Expense	$1,300,000	$1,400,000	$1,300,000

Employee_Benefit_Plans_Details

Employee Benefit Plans (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]	'	'	'
Minimum Years Of Age	'18 years	'	'
Minimum Service Requirement	'90 days	'	'
Defined Contribution Plan, Cost Recognized	$400,000	$1,500,000	$1,200,000
Defined Contribution Plan Percentage Minimum Foreign Employees	3.00%	'	'
Defined Contribution Plan Percentage Maximum Foreign Employees	31.00%	'	'
Defined Contribution Plan Percentage Minimum Foreign Management	10.00%	'	'
Defined Contribution Plan Foreign, Cost Recognized	$748,000	$724,000	$469,000

Quarterly_Results_of_Operation2

Quarterly Results of Operations (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net sales	$120,016	$115,210	$109,875	$103,948	$102,231	$95,907	$100,532	$95,618	$449,049	$394,288	$359,449
Gross profit	53,359	51,030	46,985	42,993	45,463	45,335	47,024	44,170	194,367	181,992	165,468
Income from operations	10,916	8,391	6,780	1,757	4,330	9,082	8,222	8,007	19,839	27,618	32,875
Income tax expense	1,642	833	1,253	-459	1,209	1,811	2,719	2,169	3,269	7,908	9,831
Net income	$6,540	$5,607	$3,752	$671	$641	$7,226	$6,095	$5,748	'	'	'
Basic (in dollars per share)	$0.15	$0.13	$0.09	$0.02	$0.02	$0.17	$0.14	$0.14	$0.39	$0.47	$0.59
Diluted (in dollars per share)	$0.15	$0.13	$0.09	$0.02	$0.01	$0.17	$0.14	$0.14	$0.39	$0.46	$0.58

Fair_Value_Measurements_Financ

Fair Value Measurements - Financial Assets and (Liabilities) Carried at Fair Value (Details) (USD $)	Dec. 31, 2013		Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	$1,200		$700
Fair Value, Measurements, Recurring | Estimate of Fair Value, Fair Value Disclosure	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	1,203	[1]	'
Marketable securities	'		-1,788
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	0	[1]	'
Marketable securities	'		0
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	1,203	[1]	'
Marketable securities	'		-1,788
Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3	'		'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'		'
Interest rate swap	0	[1]	'
Marketable securities	'		$0
[1]	The fair value of the interest rate swap is determined based on forward yield curves.

Fair_Value_Measurements_Liabil

Fair Value Measurements - Liability Measured on Recurring Basis, Unobservable Input Reconciliation (Details) (Contingent Consideration, USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Contingent Consideration	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'	'
Beginning balance	$6,697	$1,290
Contingent consideration liability recorded as the result of acquisitions (see Note 2)	0	4,704
Initial purchase price adjustments finalized over the period (see Note 2)	0	280
Fair value adjustments recorded to (income) expense during the period	-4,094	480
Contingent payments made	-77	-57
Ending balance	$2,526	$6,697

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value Inputs, Liabilities, Quantitative Information (Details) (Contingent Consideration, USD $)

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

In Thousands, unless otherwise specified

Income Approach Valuation Technique

Income Approach Valuation Technique

Minimum

Minimum

Maximum

Maximum

Revenue-based Payments

Revenue-based Payments

Other Payments

Other Payments

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Income Approach Valuation Technique

Income Approach Valuation Technique

Income Approach Valuation Technique

Income Approach Valuation Technique

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value, Inputs, Level 3

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate

'

'

'

5.40%

'

11.00%

10.00%

15.00%

14.50%

'

'

'

'

Contingent consideration liability

$2,526

$6,697

$1,290

'

'

'

'

'

'

$2,282

$6,370

$244

$327

Probability of milestone payment

'

'

'

90.00%

90.00%

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Narrat

Fair Value Measurements - Narrative (Details) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013
					Other Long-term Obligations	Other Long-term Obligations	Accrued Liabilities	Accrued Liabilities	Ostial Solutions, LLC	Ostial Solutions, LLC
									Developed technology	Other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'	'	'	'	'
Contingent consideration liability	'	'	'	'	$2,300,000	$5,900,000	'	'	'	'
Contingent consideration liability	'	'	'	'	'	'	274,000	723,000	'	'
Other Asset Impairment Charges	'	8,208,000	55,000	103,000	'	'	'	'	'	'
Goodwill impairment charge	'	8,089,000	'	'	'	'	'	'	'	'
Finite-lived Intangible Assets, Fair Value Disclosure	'	'	'	'	'	'	'	'	1,500,000	160,000
Impairment of cost-method investment	$2,368,000	$0	$2,368,000	$0	'	'	'	'	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	0 Months Ended	12 Months Ended
	Jun. 22, 2011	Dec. 31, 2011
Stockholders' Equity Note [Abstract]	'	'
Issuance of common stock, net of offering costs, shares	5,520,000	'
Issuance of common stock, net of offering costs	$87,700,000	$87,700,000
Underwriting Discounts and Commissions	4,600,000	'
Other Indirect Cost In Connection With Public Offering	$127,000	'

Schedule_II_Valuation_and_qual1

Schedule II - Valuation and qualifying accounts (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011		Dec. 31, 2009
Allowance for Doubtful Accounts [Member]	'		'		'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'		'
Balance at Beginning of Year	($892)		'		($464)		($593)
Additions Charged to Costs and Expenses	-376	[1]	-545	[1]	-12	[1]	'
Deduction	428	[2]	117	[2]	141	[2]	'
Balance at End of Year	-840		-892		'		-593
Valuation Allowance of Deferred Tax Assets [Member]	'		'		'		'
Movement in Valuation Allowances and Reserves [Roll Forward]	'		'		'		'
Balance at Beginning of Year	-1,225		'		-361		0
Additions Charged to Costs and Expenses	-138	[3]	-864	[3]	-361	[3]	'
Deduction	0		0		0		'
Balance at End of Year	($1,363)		($1,225)		'		$0
[1]	We record a bad debt provision based upon historical experience and a review of individual customer balances.
[2]	When an individual customer balance becomes impaired and is deemed uncollectible a deduction is made against the allowance for uncollectible accounts.
[3]	We record a valuation allowance against a deferred tax asset when it is determined that it is more likely than not that the deferred tax asset will not be realized.